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ABSTRACT 
The Human immunodeficiency virus (HIV) epidemic continues to spread globally. Approximately 
33.4 million people were living with HIV in 2008, with Sub-Saharan Africa remaining the most 
heavily affected region worldwide. This highlights the need for the development of an effective 
prophylactic HIV vaccine, most especially for developing countries. Despite more than 20 years 
of research, only a few HIV vaccines have reached phase III clinical trials, with only one of them 
showing modest protection against infection. For these reasons, multiple strategies for the 
production of an immunogenic HIV vaccine have been explored. The focus of this project is the 
use of the tuberculosis vaccine, Mycobacterium bovis bacilli-Calmette-Guerin (BCG), as an HIV 
vaccine vector. BCG has a proven safety record and is currently the most widely used vaccine, it 
stimulates a powerful immune response, is easy and cheap to manufacture since it needs limited 
purification and is one of the most heat-stable vaccines. Despite these advantages, high level 
expression of viral antigens in BCG can often increase the metabolic burden resulting in genetic 
instability and hence poor immune responses. 
 
This study aimed to compare recombinant mycobacteria expressing HIV-1 gag under the control 
of different promoters and leader sequences. This was done to determine whether the genetic 
stability of the recombinant mycobacteria could be improved by modification of these vector 
features and to gain insight into what types of immune responses may be elicited in mice. 
 
The following steps were taken to achieve the aims of this study; firstly, the optimal vector 
backbone was selected; secondly, a series of shuttle vectors were constructed to compare i) 
different promoters - hsp60, psmcyc or mtrA ii) different leader sequences - α-antigen leader 
sequence, 19kDa signal peptide or no signal peptide and iii) HIV-1 gag codon optimised for 
mycobacteria or un-codon optimized gag.  
In this study it was shown that pEM19 was an optimal vector backbone, also that addition of the 
mtrA promoter; leader sequences and codon optimized HIV-1 gag did not have an effect on 
vector fitness. However, the codon optimisation of gag was shown to enhance vector fitness (as 
compared to un-codon optimised gag). Furthermore, the use of leader peptides resulted in 
differential expression levels of Gag as shown by p24 assays.  
The last part of the study aimed at assessing the effect of fusing the 19kDa or α-antigen leader 
sequences to HIV-1 gag on the immunogenicity of recombinant BCG Pasteur ∆panCD vaccines. 
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Therefore the following vaccines were prepared: BCG Pasteur ∆panCD [pEMαGag2V3SV5] 
(Gag is fused to the α-antigen leader sequence), BCG Pasteur ∆panCD [pEM19Gag2V3SV5] 
(Gag is fused to the 19kDa leader sequence) and BCG Pasteur ∆panCD [pEMGag2V3SV5] (Gag 
with no leader sequence). The vaccination strategy employed a prime with the aforementioned 
rBCG vaccines followed by a boost (28 days post priming) with SAAVI MVA-C to determine 
cellular immune responses elicited. SAAVI MVA-C is a recombinant modified vaccinia Ankara 
(MVA) vaccine that expresses an HIV-1 subtype C polyprotein Gag-RT-Tat-Nef (Grttn) and a 
truncated Env (gp150CT). A boost of the response to the V3CTL peptide (1.8 fold above the 
control) was achieved with a BCG Pasteur ∆panCD [pEMαGag2V3SV5] prime and SAAVI 
MVA-C boost but no boost of the response of the Gag peptides was observed. For a prime with 
the BCG Pasteur ∆panCD [pEM19Gag2V3SV5] vaccine, a boost of the response to the Gag CD8 
peptide was observed (5 fold above the control). No boost response was detected when BCG 
Pasteur ∆panCD [pEMGag2V3SV5] was used as the priming vaccine. 
 
Despite the generally low immune responses elicited by the rBCG vaccines, the BCG Pasteur 
∆panCD [pEMαGag2V3SV5] maybe a promising vaccine as seen by increased immune 
responses to the V3 CTL epitope. M. smegmatis [pEMαGag2V3SV5] also showed higher 
expression levels of Gag p24 than the other recombinants. In this study various signal peptides 
and the mtrA promoter were included in the vectors, therefore future studies could include the 
comparison of Gag expression and localization from these rBCG vaccines upon infection of 
macrophages in order to better understand the relationship between antigen presentation and the 
nature of the immune response elicited.  
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CHAPTER 1: INTRODUCTION 
1.1. Global impact of HIV and AIDS 
The human immunodeficiency virus (HIV) epidemic continues to spread globally; whereby there 
were approximately 33.4 million people were living with HIV in 2008. Sixty per cent, of HIV-
positive people were female, with Sub-Saharan Africa remaining the most heavily affected 
region worldwide. This region accounted for over two thirds (67%) of all people living with HIV 
and for nearly three quarters (72%) of AIDS-related deaths in 2008. In Sub-Saharan Africa, there 
were 2.2  million new infections and an estimated 2.1 million adult and child deaths due to HIV 
in 2007, resulting in reduced life expectancy, slowed economic growth and increased poverty 
(Spearman et al. 2009, UNAIDS 2009). In 2008, 14 million children had lost one or both parents 
due to AIDS. With introduction of highly active anti-retroviral therapy (HAART), adult (14-49 
years) prevalence rates in Sub-Saharan countries declined from 5.8% in 2006 to 5.2% in 2008.  
About 7 million people in the sub-Saharan region were in need of ART in 2007, however, only 
44% of this population had access to treatment by the nd of 2008 (WHO, Public Health 
Mapping and GIS Map Library 2009). Furthermore, the improved quality of life and life 
expectancy of HIV-infected individuals, as well as reduction in incidences of opportunistic 
infections has been correlated with a widespread use of ART (d'Arminio Monforte et al. 2005, 
Depairon et al. 2001, Detels et al. 2001, Zuniga et al. 2007). However, adverse side effects of 
ART, complex and prolonged dose schedules have lead to incomplete adherence and subsequent 
emergence of drug-resistant viral strains (Burda et al. 2010, Chaplin et al. 2010, Castelbranco et 
al. 2010, Descamps et al. 2010, Kandathil et al. 2009, Santoro et al. 2008), which may also be 
transmitted to ART-naïve individuals (Descamps et al. 2010). For instance, it has been shown 
that 60% of protease inhibitor users contracted diseases caused by metabolic changes such as 
dyslipidemia, insulin resistance and diabetes Miletus, which are the risk factors for 
cardiovascular disease (Depairon et al. 2001, Christeff et al. 2002).  
 
Several factors, including the continuous genetic and antigenic diversity of HIV, integration of 
HIV proviral DNA into the host-cell genome, and the early establishment of latent viral 
reservoirs are some of the factors that hamper treatment of HIV infections (Ross et al. 2010). 
Generally, viruses associated with chronic infections co-exist with the host‟s immune system for 
years and only cause disease at the late stage. Therefore, to avoid the late stage disease incident, 
an immune response can be induced prior to infection by means of vaccination. This 
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phenomenon has been successfully exploited in prevention of other chronic infections such as 
human papillomavirus infections (FUTURE I/II Study Group et al. 2010) and herpes zoster 
(Hambleton et al. 2008). Taken together, these highlight the need for development of an effective 
HIV vaccine, most especially for the developing countries, with greater disease burden. 
 
1.2. The value of induction of both humoral and cellular immune responses 
in HIV vaccine development 
While education and behavioral modifications are amongst the important aspects in controlling 
the HIV epidemic, there is still an urgent need for the development of an effective HIV-1 
vaccine. Despite more than 20 years of research,  Rv144 vaccine  ( priming with ALVAX-HIV; 
a canarypox vector expressing HIV-1 Gag and Protease as well as Gp120 from Clade E and 
boosting with AIDSVAX B/E; rgp120 subunit vaccine) is the only HIV-1 vaccine that shows 
limited but significant efficacy to prevent HIV acquisition in human clinical trials (Rerks-Ngarm 
et al. 2009). These limited successes of HIV-1 vaccines have emphasized the need for increased 
knowledge with regard to fundamental immunity against HIV-1 and have provided insights for 
vaccine strategies that may be implemented for designing more effective HIV-1 vaccines in the 
future.  
 
Over the years, the HIV vaccine development community has followed the three overlapping 
routes of vaccine development. The first being the use of candidate vaccines aimed at inducing 
neutralizing antibodies. Such vaccines were typically subunit vaccines. It was however 
discovered that neutralizing antibodies failed to neutralize primary HIV isolates (Ching et al. 
2008). These vaccines also failed to protect healthy individuals as well as non-human primates 
from infection (Cho et al. 2001, Cho et al. 2001, Flynn et al. 2005, Pitisuttithum et al. 2006, 
Gilbert et al. 2005). The second route focused on the use of HIV vaccines that elicited mainly T-
cell responses, which were found to be vital in early and subsequent control of both HIV and 
SIV in humans and non-human primates respectively (Manrique et al. 2008, Manrique et al. 
2009, Sircar et al. 2010, Valor et al. 2008). However, this type of immunity is deemed to control 
infection, but does not result in complete clearance of HIV. Furthermore, mutations in the T-cell 
epitopes may arise, thus allowing for viral escape from the immune response (Barouch et al. 
2003, Kemal et al. 2008). Finally, heterologous prime-boost regimes have been employed to 
induce both humoral and cellular immune responses (Rerks-Ngarm et al. 2009). The prime-boost 
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regime has also been attributed to an increased CD4+ response, thus mounting the long term 
memory response by the CTL and resulting in high neutralizing antibody titres (Amara et al. 
2002). 
 
Recent studies have shown that important factors governing the induction of protective immunity 
against HIV-1 include: robust mucosal immunity (Sircar et al. 2010), polyfunctional T cells 
(Valor et al. 2008), and broadly neutralizing antibodies from highly conserved glycoprotein 
epitopes, which have been mostly unable to neutralize heterologous viruses, but have 
emphasized the possible use of polyvalent, genetically diverse immunogens (Cho et al. 2001, 
Powell et al. 2010)  
 
One of the important factors to consider when developing a vaccine for the developing countries 
is the issue of helminth infections, which result in CD4+ T-cell population skewed towards T-
helper type 2 (Th2) as well as expansion of T-regulatory cells and some level of immune 
suppression/anergy (Da'dara, Harn 2010, Da'Dara et al. 2006, McKee, Pearce 2004, Taylor et al. 
2006). Therefore, such infections need to be addressed before vaccination in order to induce 
protective immunity against HIV. Optimal delivery methods of DNA vaccines (Liu et al. 2008, 
Luckay et al. 2007) and also understanding the core immune responses mediating protection 
against simian immunodeficiency viruses (SIV) and HIV-1 in animal models following 
vaccination (Manrique et al. 2009, Hansen et al. 2009), are also the key aspects to be regarded 
for designing more effective HIV-1 vaccines in the future. 
 
A clear understanding of HIV-1 biology and viral characteristics has enlightened the 
development of safe and effective HIV-1 vaccines (Devadas et al. 2007). Cell associated viral 
infections are mostly cleared by the cellular immune responses, while humoral responses are 
mainly elicited by extra-cellular parasites (Rouse et al. 1988, Ziegelbauer, Overath 1993). The 
HIV life cycle entails both intracellular and extracellular stages and is mainly transmitted via the 
mucosal surfaces; therefore an effective vaccine against HIV should be capable of inducing 
systemic and mucosal immunity including both cellular and humoral responses (Spearman et al. 
2009, Fauci et al. 2008).   
1.3. Phase III trials and their implications in HIV vaccine development 
Despite more than 20 years of research, only a few HIV vaccines have reached the phase III 
clinical trials, with only one of them showing modest protection against infection (Rerks-Ngarm 
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et al. 2009, Flynn et al. 2005, Pitisuttithum et al. 2006). Viral characteristics as well as poorly 
understood correlates of protection are some of the factors that hamper the development of a safe 
and immunogenic vaccine. Several pilot (phase IIB) studies have been conducted in order to 
evaluate vaccine safety and efficacy in humans. Due to the vast breadth of the topic, only a few 
of these vaccine trials will be reviewed.  
 
The phase IIB trial (Merck (STEP) study) where a recombinant adenovirus vector (Ad5) 
expressing HIV-1 gag, pol and nef was used as vaccine was conducted in 2007, where about 3 
000 HIV-1 negative individuals who were at high risk of infection in America and Australia 
were enrolled. Despite the elicited cell mediated responses, the vaccine did not prevent HIV-1 
infection (Buchbinder et al. 2008). Unfortunately, the Merck study (STEP) was stopped due to 
possible higher rates of HIV-1 infection in vaccinees (Buchbinder et al. 2008). Graham et al. 
(1996) also evaluated the safety and immunogenicity of the envelope based (gp120 from HIV-1 
Subtype B) vaccine formulated in emulsifier MFP59, with or without a biological response 
modifier MTP-PE. In this phase II study, 49 healthy adults who were at low risk of exposure to 
HIV-1 were enrolled with the aim of providing pilot data for anticipated phase III trials in HIV-1 
infected pregnant women and to also investigate the role of vaccination schedule on immune 
responses. This group discovered that individuals who received vaccination with modifier 
showed increased local and systemic side effects. The vaccine was also able to induce CD8
+
 T-
cell responses that were vital for HIV-1 clearance (Graham et al. 1996). From this study, it was 
discovered that vaccination schedule played an important role in induction of antibody 
responses; frequent (monthly) vaccination may result in diminished antibody responses as well 
as attenuated cellular immune responses. On the contrary, longer vaccination intervals resulted in 
higher antibody titers and lymphoproliferative activity (Graham et al. 1996). However, the serum 
from the participants was unable to elicit antibody response with the neutralizing effect on HIV-
1 primary isolates grown in PBMCs, irrespective of its safety and immunogenicity (Graham et 
al. 1996). Graham and his co-workers (1996) postulated that the vaccine could be formulated in 
another adjuvant to lower the side effects, the envelope based vaccine could be used as a booster 
in heterologous prime-boost regime to increase the breadth and magnitude of both humoral and 
cell mediated immune responses, and finally bivalent instead of monovalent gp120 vaccine may 
be ideal. 
 
From these data, the world‟s first phase III vaccine efficacy trials were carried out on bivalent 
glycoprotein gp120 (AIDSVAX B/B and AIDSVAX B/E). The AIDSVAX B/B contained two 
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recombinant gp120 HIV-1 subtype B antigens that were adsorbed to alum. This vaccine 
(VAX004) advanced to phase III clinical trials in 1998-1999 and was administered to healthy 
individuals in North America and the Netherlands (Flynn et al. 2005). The participants were at 
high risk of infection via either homosexual or heterosexual exposure. In total, 5417 participants 
were enrolled in this study, with 94% of these being males. Administration of the vaccine lead to 
mild to moderate reactogenicity occurring in the first 3 days post vaccination (Flynn et al. 2005). 
This is in contrast to the pilot study done by Graham et al. (1996), where participants who 
received monovalent gp120 vaccine with adjuvant (MFP-PE) experienced increased local and 
systemic side effects, thereby highlighting the possible importance of using a better adjuvant in 
vaccine formulations. 
 
A 100% of all vaccinees developed type-specific neutralizing antibody responses against the SF-
2 strain of HIV-1 and CD4 blocking antibodies (Graham et al. 1996), thus indicating the 
vaccine‟s immunogenicity. However, the bivalent vaccine was ineffective in preventing HIV-1 
infection or in modifying markers of disease progression. Flynn et al. 2005 postulated that failure 
of this vaccine maybe attributed to lack of induction of antibodies capable of neutralizing 
genetically diverse HIV-1 primary isolates, which has also been shown by a monvalent gp120 
vaccine (Graham et al. 1996). Another bivalent gp120-based vaccine candidate was in the 
pipeline. This vaccine was made from gp120 proteins from genetically diverse HIV-1 subtypes B 
and E isolates (Berman et al. 1999). From this pilot study, the following observations were made. 
Firstly, the use of genetically diverse subtypes may expand the breadth of neutralizing antibodies 
as compared to monovalent as well as bivalent vaccines with antigens isolated from the same 
subtype (Flynn et al. 2005, Graham et al. 1996). Secondly, the quality and magnitude of antibody 
responses elicited by bivalent vaccines are similar to those observed in sera from HIV-1 infected 
people, and lastly, antisera to gp120 vaccine can elicit antibodies neutralizing both T-cell and 
macrophage tropic viruses.  
 
This vaccine (VAX003) then advanced to phase III trials that were conducted in injection drug 
users (IUDs) in Thailand. In this study, 2546 IUDs were enrolled between 1999 and 2000, with 
93% being males. Similar to the AIDSVAX B/B; the vaccine was administered with alum as an 
adjuvant. In terms of safety, the vaccinees showed mild tenderness at the site of injection. 
Despite the advantages of AIDSVAX B/E as observed by Berman et al. (1999), just like the 
AIDSVAX B/B, the vaccine did not prevent HIV-1 infection or delay disease progression 
(Pitisuttithum et al. 2006). Comparing the two trails, in the VAX004, an interesting trend toward 
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modest efficacy was observed as opposed to the VAX003 trial, with the vaccine efficacy of the 
former and latter being 6% and 0.1% respectively (Flynn et al. 2005, Pitisuttithum et al. 2006), 
thereby implying that both vaccines were ineffective in preventing HIV-1 infection. 
 
 Despite their safety, inability of these monovalent and bivalent gp120 based vaccines to 
neutralize primary HIV-1 isolates brought forward a number of postulations with regards to use 
of glycoprotein vaccines; the use of oligemeric glycoproteins as opposed to either monovalent or 
bivalent ones (Thongcharoen et al. 2007), the use of better adjuvant or immunoglobulins to 
enhance immunogenicity as well as their use as boosters in prime-boost regimen to elicit both B- 
and T-cell mediated immunogenicity (Rerks-Ngarm et al. 2009, Nkolola et al. 2010, Shimada et 
al. 2010). 
 
The last strategy was employed in the world‟s largest phase III trial (RV144), where a canary 
pox-based (ALAVAC-HIV) and AIDSVAX B/E vaccines were used in the prime-boost regime. 
A total of 16 402 HIV-1 negative individuals were enrolled in Thailand in 2003, with 63% being 
men. The aim of the study was to evaluate the vaccines‟ ability to prevent HIV-1 infection and to 
evaluate its effect on viral loads post acute infection. There were no significant differences in 
viral loads or CD4
+
 T-cell counts post infection between vaccine and placebo groups. Most 
importantly, the study showed a significant, modest reduction in the rate of HIV-1 infection in 
vaccinees as compared with placebo, with a vaccine efficacy of 26.4% (Rerks-Ngarm et al. 
2009), as compared to 6% and 0.1% following vaccination with AIDSVAXB/B and AIDSVAX 
B/E respectively (Flynn et al. 2005, Pitisuttithum et al. 2006, Gilbert et al. 2005). This study is 
therefore the first successful phase III clinical trial, whereby protection from infection was seen. 
Rerks-Ngarm et al. (2009) proposed certain issues to be addressed concerning the results 
obtained from this study; evaluation of the vaccine efficacy in low risk groups (which may be 
increased) and the long-term effects of vaccination. 
 
Taken together, these studies highlight, firstly, the importance of choice of better adjuvants to 
enhance glycoprotein immunogenicity, secondly, the shift from use of monovalent to either 
bivalent or oligomeric recombinant gp120 vaccines to increase the breadth of neutralizing 
antibodies. Lastly and most importantly the use of these bivalent or oligomeric vaccines as 
boosters in the heterologous prime-boost vaccination regimen, which in turn may elicit broadly 
neutralizing antibodies as well as T-cell mediated immune responses that are needed for HIV-1 
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infection. This limited success of HIV-1 vaccines has also highlighted the importance of 
understanding the correlates of protection in finding safe and effective HIV-1 vaccines.  
1.4. Elite controllers and their information on control of HIV infection 
Following the discovery of HIV-1 as a cause for AIDS, a small group of individuals with HIV 
were found to maintain high CD4
+
 T-cell counts over many years in the absence of ART and 
therefore did not progress towards AIDS. This group was termed “long-term nonprogressors” 
(Buchbinder et al. 1994). Most studies have now focused on individuals who maintain 
undetectable (<50copies/ml) or low (<2000copies/ml) viral loads, termed “elite or viremic 
controllers” respectively (Grabar et al. 2009, Okulicz et al. 2009). Postulations of mechanisms by 
which such individuals control viral replication may be informative in the HIV-1 vaccine efforts 
and these include; lack or reduced CD4
+
 T-cell susceptibility to infection (Saez-Cirion et al. 
2006), infection of individuals by replication-deficient viruses (Saez-Cirion et al. 2009) and 
efficient control of viral replication by the immune response (Saez-Cirion et al. 2006, Julg et al. 
2010).  
 
To test the above hypotheses, Julg et al. (2010) purified CD4
+
 T-cells (depleted CD8
+
 T-cells) 
and showed that the elite controllers had CD4
+
 T-cells that were readily infected by X4 tropic 
viruses to a similar degree to those from the uninfected individuals, thereby highlighting lack of 
resistance to infection of CD4
+
 T-cells from elite controllers. Studies also revealed that 
replication-competent viruses could only be isolated from minority (3 out of 14) of elite 
controllers, suggesting that the majority of these individuals may be infected with replication-
deficient viruses or there may be a limited availability of HIV-1 infected CD4
+
 T-cells in the 
PBMCs of these elite controllers, thus making it difficult to capture infected cells in a given 
PBMC sample (Julg et al. 2010).  
 
To show that elite controllers may have reduced frequency of susceptible CD4
+
 T-cells, the 
proviral DNA levels in elite controllers‟ PBMCs was compared to that of PBMCs from viraemic 
controllers and chronic progressors (Julg et al. 2010). This study showed low viral reservoirs in 
elite controller CD4
+
 T-cells, rather than infection with replication-defective viruses. This was 
supported by another study whereby replication-competent viruses were isolated from elite 
controllers (Blankson et al. 2007).  
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These studies therefore indicate that the postulations that in elite controllers there is lack of or 
limited susceptible CD4 cells and also that these individuals may be infected with mostly 
replication-deficient viruses may not entirely be true, thereby implying that cellular restriction 
factors may not be the major cause of long-term nonprogression. Therefore another possible 
mechanism may be that elite controllers exhibit efficient and durable immune control of the virus 
also CTL selection pressure on gag-protease alters viral replication capacity (Julg et al. 2010), 
and that HIV-specific CTLs inducing escape mutations with fitness costs in this region may be 
important for strict viremia control (Saez-Cirion et al. 2009, Miura et al. 2009). Soon after HIV-1 
infection, elite controllers are able to down-regulate viral replication in lymphoid tissue, thus 
reducing the number of infected cells, which in turn will result in low plasma viral RNA levels, 
very few circulating HIV-1 infected CD4 cells (as seen by low proviral DNA levels), thus 
leading to slow rates of disease progression (Julg et al. 2010). 
  
How do these findings help in the quest for finding an effective HIV-1 vaccine? Firstly, they 
shed the light on how elite controllers manage to control their infection. Secondly, the 
relationship between ongoing replication and disease progression is enlightened. Lastly, these 
studies provide strong support for emerging efforts to manipulate the immune system to achieve 
a long‐term control of HIV replication similar to what is seen in elite controllers in the absence 
of antiretroviral therapy. 
 
1.5. HIV vaccine vectors and vaccination strategies   
During the past two decades, multiple strategies for the production of an immunogenic HIV 
vaccine have been explored. Various organisms have therefore been used as antigen delivery 
systems and have been implemented in prime-boost vaccination regimes and in single dose 
vaccinations. When used in single dose regimen, these vectors elicit mostly only one arm of the 
immune response (either cellular or humoral immune responses), thus limiting the 
immunogenicity of the expressed antigens, thereby emphasizing the importance of heterologous 
prime-boost regimes. Induction of broadly neutralizing antibodies is one of the important factors 
governing the induction of protective immunity against HIV-1. It has been shown that 
monomeric glycoprotein immunogens do not elicit broadly neutralizing antibodies in animal 
models and humans (Flynn et al. 2005, Pitisuttithum et al. 2006), thus several groups have 
focused on generating trimer proteins (Nkolola et al. 2010, Li et al. 2007). Some of the HIV 
vaccine vectors and vaccine strategies are briefly reviewed in Sections 1.5.1 to 1.5.6.  
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1.5.1. Viral vectors  
The highly attenuated recombinant MVA, NYVAC and canarypox vectors are replication 
deficient in non-avian hosts. These poxvirus-based vaccines are extremely safe and well 
tolerated in animal models (Garcia-Arriaza et al. 2010, Mooij et al. 2008) and human volunteers 
(Rerks-Ngarm et al. 2009).  
 
Replicating and persistent herpes viral vectors such as cytomegalovirus and adenovirus have 
been used to express SIV antigens. These have been shown to induce strong effector memory T-
cell responses, which may potentially decrease HIV acquisition after sexual exposure (Hansen et 
al. 2009). Macaque studies have shown that vaccination with replicating cytomegalovirus and 
adenovirus vectors resulted in increased immune responses that reduced viral loads and slowed 
disease progression following challenge with SIV (Hansen et al. 2009, Patterson et al. 2008). 
 
The measles virus has also been used to express SIV genes. This vector induces long-lasting 
specific responses in mice (Liniger et al. 2009) and non-human primates (Zuniga et al. 2007), 
and because the vector is based on the traditional live-attenuated measles vaccine, it has the 
benefit of a well-established safety profile and can be used as an injectable or aerosol vaccine 
(Dilraj et al. 2007). Additionally, MV genome is not translocated into the nucleus which 
avoids viral genome integration into host cell genome, adding to the safety profile of the vaccine. 
 
1.5.2. Virus like particles 
Virus-like particle vaccines (pseudovirion vaccines) have also been developed as non-infectious 
HIV pseudovirions that may encode one or more, but not all HIV proteins, such as Gag. These 
virus-like particles allow for the antigens to be presented in a non-infectious form and may also 
induce neutralizing antibodies against homologous primary isolates (Hammonds et al., 2003). 
However, low antigen-specific and antibody responses have been attributed to use of VLPs 
alone, thus emphasizing the requirement of a boosting vaccine to elicit high antibody titres and 
broad magnitude antigen-specific immune responses (Chege et al. 2008, Chege et al. 2009). 
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1.5.3. Envelope-based vaccines  
Envelope-based vaccines are mostly derived from HIV surface antigens such as gp120, gp140 or 
gp160 (Falk et al. 2000, Hamajima et al. 1997). These vaccines are not infectious, so they can 
safely be given to immunocompromised people and are less likely to induce unfavorable immune 
reactions provided the extraction procedure and detoxifying methods yield a pure product 
(Liljeqvist, Stahl 1999). However, expressed antigens do not usually stimulate as strong immune 
responses as organisms and therefore mostly require the use of adjuvants to enhance their 
immunogenicity (Spearman et al. 2009, Nkolola et al. 2010). 
 
1.5.4. DNA vaccines  
Similarly, lack of optimal delivery of the DNA into cells particularly in larger animals and the 
inability to induce robust antigen specific immune responses in non-human primates hampers the 
choice of these vaccines (Luckay et al. 2007). Therefore the potency of DNA vaccines has been 
improved by use of adjuvant technology (plasmid cytokine as well as chemokine adjuvant), 
improved delivery methods (in vivo electro-poration) and plasmid optimization (foreign gene 
codon optimization) (Liu et al. 2008, Shimada et al. 2010). Since the host organism expresses the 
foreign DNA, DNA vaccines are postulated to be extremely safe and devoid of side effects, 
thereby highlighting the importance and relevance of this technology (Tenbusch et al. 2010).  
 
1.5.5. Viral sequences used in HIV vaccines   
Apart from focusing on development of the best HIV vaccine vector or improved vaccination 
strategy, the HIV vaccine development community has also sought to determine viral antigens 
that would elicit protective immune responses (Doria-Rose et al. 2005, Kothe et al. 2006).  
Ancestral sequences, which are re-created parental sequences for a particular lineage, as well as 
alignment of circulating primary HIV isolates in order to select for most common residue at each 
position to generate consensus sequences, are some of the strategies employed to identify viral 
antigens that elicit protective immune responses (Doria-Rose et al. 2005, Kothe et al. 2006). 
Ancestral sequences may include recently fixed escape mutations (Gaschen et al. 2002), whereas 
post translational modifications may arise from consensus sequences (Doria-Rose et al. 2005) 
thus making such technologies prone to sampling bias. This in turn may limit antigenicity and 
immunogenicity of these sequences (Gao et al. 2005, Kothe et al. 2007).    
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A broad T-cell response is said to be important in control of viral replication (Kiepiela et al. 
2007), therefore polyvalent „mosaic‟ antigens, which are assembled natural sequences from a 
defined viral population optimized to contain a high number of potential T-cell epitopes (PTE) is 
a promising approach in the HIV vaccine development community (Fischer et al. 2007).  These 
full-length proteins are designed such that the natural antigen expression and processing is 
maintained. Because these PTE peptides include overlapping sequences that reflect naturally 
occurring HIV polymorphisms (Li et al. 2006), their responses entail both the recognition of a 
particular epitope (breadth) and the cross-recognition of variants of that epitope (depth) (Barouch 
et al. 2010). For example, when encoded by recombinant adenovirus, such sequences (mosaic 
Gag, Pol and Env sequences) induced CD8
+
 and CD4
+
 T-cell responses that were almost four 
times higher than those elicited by consensus or natural sequences. Moreover, their magnitude 
was comparable to that of both natural and consensus sequences, thereby emphasizing that the 
mosaic antigens expanded cellular immune breadth and depth without compromising the 
magnitude of individual epitope-specific responses (Barouch et al. 2010). 
 
1.5.6. Prime-boost regimes  
The heterologous prime-boost regimes have also been employed as vaccination strategies in 
order to induce both the humoral and cellular immune responses (Nkolola et al. 2010, Garcia-
Arriaza et al. 2010).  Since this in study the prime-boost regime was used, Table 1.1, which 
shows some of the recent prime-boost vaccination strategies using vectors that express one or 
more of the HIV genes as well as the use of glycoproteins as HIV-1 vaccines, is included in this 
review. The immunogenicity of these vaccines or vaccination strategies was assessed in animal 
models.   
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Table 1.1: Some of the key publications of the prime-boost vaccination strategies using vectors that express one or 
more of the HIV genes 
  
Vector/vaccinati
on strategy  
HIV/SIV 
genes/antigens 
Experimental design Animal 
model 
Key findings reference 
DNA prime, 
Double deletion 
mutant (MVA-B 
ΔA41L/ΔB16R) 
boost 
HIV-1 subtype 
B gp120 and 
polypeptide 
genes; gag-pol-
nef  
i.m priming of 
BALB/c mice with 
DNA-B (100μg), i.p 
boosting with MVA-
B recombinant virus 
(1x10
7
pfu/mouse). 
Control mice were 
primed with sham 
DNA and boosted 
with wt MVA. 
BALB/c 
mice  
Both vectors triggered 
CD8
+
 and CD4
+
 T-cell 
responses, with over 
91.9% of these being 
CD8
+ 
T-cell responses. 
MVA-B mutant elicited 
polyfuctional, broad 
magnitude CD8
+ 
T-cell 
responses. Both vectors 
elicited polyfunctional 
env-specific CD4
+
 T-cell 
responses.  
(Garcia-
Arriaza et 
al. 2010) 
DNA prime, 
Vaccinia virus 
(NYVAC89.6P-
SIVGPN) or 
Modified 
Vaccinia Ankara 
(MVA89.6P-
SIVGPN) boost 
SIVmac239 gag-
pol-nef and 
SHIV89.6P env, 
driven by the 
two early/late 
promoters in 
back-to-back 
orientation 
individually 
i.m DNA vaccine 
(4mg) administered 
at 0 and 4wks. 
Control animals were 
given empty vector 
DNA vaccine. At 
wks 20 and 24, 
animals were boosted 
with either 
NYVAC89.6P-
SIVGPN or 
MVA89.6P-SIVGPN 
(5x10
8
pfu/mouse). 
Control groups 
received an empty 
NYVAC vector as a 
boost. Macaques 
were challenged with 
pathogenic SHIV89.6P 
(MID50)  
Rhesus 
macaques 
Dominant (CM and EM 
phenotypes) env-specific 
responses elicited by 
DNA priming in both 
groups. MVA boost 
resulted in both 
polyfuctional CD8
+
 and 
CD4
+
 T-cell responses, 
while NYVAC elicited 
mainly CD4
+
 T-cell 
responses specific to 
Gag. Similar levels of 
protection were seen in 
both groups, where the 
animals were able to 
control VL and 
maintained CD4
+
 T-cell 
numbers. 
(Mooij et 
al. 2008) 
Adenovirus 
(Ad5hr) prime, 
gp120 peptide 
boost 
HIV env89.6P 
gp140ΔCFI, 
SIVgag239/SIVn
ef239, HIV89.6P 
peptomer 
At wks 0 and 12, 
animals were primed 
with Ad5hr 
i.n/i.t/orally at a total 
recombinant of 
1.5x10
9
pfu/macaque/
route. Animals were 
boosted with various 
peptides with/without 
adjuvant at wks 24 
and 36 post priming. 
Control group 
received empty 
vector (Ad5hrΔE3) 
Mamu-
A*01 
negative 
macaques 
Significant reduction in 
VL was seen in gp140-
boosted group. There 
was also better 
protection in this group 
due to persistent binding 
Abs as well as 
anamnestic SIV-specific 
T-cell responses. A 
siginificant reduction in 
chronic viremia 
following challenge was 
attributed to Ad 
recombinant priming 
alone. Detectable env-
(Patterso
n et al. 
2008) 
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specific proliferative 
responses, which 
gradually peaked 32wks 
post priming without 
boosting.    
Vesicular 
somitatis virus 
(VSV) prime, 
rMVA boost   
Both vectors 
expressed 
SHIV89.6P env, 
gag and pol 
Animals were primed 
with rVSV and 
boosted with rMVA 
(2x10
7
pfu/ml). The 
vaccination routes 
were i.m/i.t/oral  
Rhesus 
macaques 
Prime-boost with 
VSV/MVA generated 
solid control of SHIV 
challenge for at least 5 
years. These animals 
remained healthy, had 
normal CD4
+
 T-cell 
counts and their VL fell 
below detection limit by 
5 months. SHIV 
neutralizing Abs were 
maintained in the serum 
out to 5 years post 
challenge, thus possible 
contributing to control of 
challenge.  
(Schell et 
al. 2009) 
DNA (pTHgag) 
priming, 
recombinant 
baculovirus 
Pr55
gag
 VLPs 
boosting 
HIV-1 subtype 
C gag of Du422 
Animals were primed 
with pTHgag 
(5mg/dose) and 
boosted with Gag 
VLPs (29μg/dose). 
Some groups were 
vaccinated with 
either pTHgag or 
GagVLPs only.  
Chacma 
baboons 
Low Gag-specific and 
Ab responses to 
vaccinations with 
DNA/VLPs alone. 
Increased DNA 
inoculations did not have 
a positive effect on 
cellular or humoral 
immune responses. 
DNA/VLPs regime 
resulted in high Ab titers 
as well as broad 
magnitude Gag-specific 
responses. Recall 
responses of baboon 
PBMCs following boost 
were to peptides 
containing epitopes 
recognized by HIV-1 
subtype C-infected 
individuals.    
(Chege et 
al. 2008) 
Env gp120Ig 
(HIV Env fused 
to 
immunoglobulin) 
HIV gp120 with 
immunoglobulin 
attached to the 
N-/C-terminus, 
CMV-1E 
enhancer, driven 
by chickβ –actin 
promoter 
The following 
plasmids; pgp120, 
pgp120Ig and pIg-
gp120 were 
constructed. Animals 
were injected (i.m) 
with the expression 
plasmids (100μg). 
Control groups 
received mock 
plasmid (pCAGGS). 
BALB/c 
mice  
DNA vaccine encoding 
Gp120 with Ig fused at 
the C-terminus resulted 
in increased expression 
levels of Gp120 in both 
cell lysate and 
supernatant, enhanced 
CD8+ T-cell responses 
and provided effective 
protection against 
chimeric virus (as seen 
(Shimada 
et al. 
2010) 
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The animals were 
then boosted with the 
same plasmids. In 
some groups, mice 
were subjected to 
electric pulses at 
injection sites by a 
gene gun. At wk 6, 
mice were challenged 
with vaccinia virus 
vPE16 (1x10
7
pfu) 
expressing HIV-1 
gp160.  
by the decline in VL). 
DNA vaccination was 
dose dependant 
(decreased DNA resulted 
in increased immune 
responses).   
Clades A and C 
Trimeric Env 
gp140 with Ribi 
adjuvant prime, 
rAd26 expressing 
the same trimers 
boost (DNA 
vaccine was also 
used as a prime). 
Clade A and C 
gp140 trimmers 
with the C-
terminal T4 
bacteriophage 
fribritin 
trimerisation 
domains and 
poly-His mitifs   
The trimmers were 
extracted and purified 
using nickel columns 
and concentrated. 
Animals were 
immunized 
(100μg/animal) with 
trimmers at 4/5-wk 
intervals with 
adjuvant (s.c and i.p). 
In some experiments, 
DNA/trimmers or 
DNA/Ad26 prime-
boost regimen were 
followed.   
Guinea 
pigs 
Trimmers with adjuvant 
elicited potent, cross-
Clade NAbs responses 
against tier 1 viruses as 
well as low, but 
detectable NAbs to tier 2 
viruses of Clades A, B 
and C (most especially 
Clade C trimmers). 
DNA/trimmers or 
DNA/Ad26 prime-boost 
regimen did not show 
enhanced magnitude and 
breadth of NAbs.  
(Nkolola 
et al. 
2010) 
i.m: intra mascular, i.n: intra nasal, i.p: intra peritoneal, i.t: intra tracheal, s.c: subcutaneous, VL: viral loads, Abs: 
antibodies, NAbs: neutralizing antibodies, VLPs: virus-like particles, CMV: cytomegalovirus, wk: week, poly-His: 
poly histidine.  
 
These vaccination strategies differentially elicit one or both arms of the immune system. Some of 
these may also trigger mucosal immunity, which is ideal for the development of HIV vaccines. 
 
1.6. Development of rBCG as an HIV vaccine vector  
BCG was developed as an anti-tuberculosis vaccine at the Institut Pasteur de Lille in France 
between 1904 and 1908 by serial passaging of a virulent strain of Mycobacterium bovis to attain 
an attenuated strain named bacille-Calmette-Gu`erin (BCG) (Hoft 1996). Several features make 
BCG a good candidate as an antigen delivery system for heterologous antigens. BCG has a 
proven safety record and is currently the most widely used vaccine. Over 3 billion people have 
been vaccinated with BCG since 1921, with very low occurrences of severe complications (Hoft 
1996). As a live bacterial vaccine, BCG is easy and cheap to manufacture because it needs 
limited purification. This vaccine is one of the most heat-stable vaccines. It is a strong adjuvant 
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that can be administered at or any time after birth and is least affected by the maternal 
antibodies, with a single dose sensitizing to tuberculosis proteins for 5 to 50 years (Ohara, 
Yamada 2001). In the early studies, BCG has been extensively exploited as a delivery system for 
various viral, bacterial, human and non-human primate antigens (Falk et al. 2000, Badell et al. 
2009, Bastos et al. 2002, Kanekiyo et al. 2005).  
 
Earlier studies have also shown its ability to induce both humoral and cellular immune responses 
in animals when used in heterologous prime-boost regimens. Heterologous prime-boost with 
rBCG and various other vectors like MVA have resulted in increased immunogenicity compared 
to vaccination with rBCG alone (Ami et al. 2005, Vordermeier et al. 2004). Vordermeier et al. 
(2004) showed that heterologous prime-boost vaccination using rBCG and rMVA expressing 
Ag85A resulted in increased antigen specific CD8 T-cell responses in comparison to vaccination 
with rBCG vaccination alone. Furthermore, priming with rBCG-SIVgag and boosting with 
recombinant vaccinia virus expressing HIV Gag elicited protective immunity against mucosal 
challenge with pathogenic SIV for a year (Ami et al. 2005). 
 
Recent studies have shown that priming with rBCG and boosting with viral vectors such as 
vaccinia both expressing HIV antigens may result in induction of CD4
+
 and CD8
+ 
T-cell-specific 
cytokines (Promkhatkaew et al. 2009). Similarly the rBCG prime and Pr55
gag
 boost regime 
elicited predominant CD8
+ 
T-cell responses as well as antigen-specific humoral immune 
responses (Chege et al. 2009). BCG has also been used to express SIV antigens and its 
immunogenicity has been evaluated in animal models. This resulted in more persistent, 
polyfuctional SIV-specific cellular responses in rhesus macaques boosted with rAd5 (Cayabyab 
et al. 2009), the production of long-lasting SIV-Gag-specific serum IgG in guinea pigs 
(Kawahara et al. 2002). Rosario et al. (2010) evaluated the safety and immunogenicity of novel 
rBCG-HIV and rMVA-HIV vaccines in neonate rhesus macaques. All the vaccines were safe, 
with mild local reactions at the site of injection and showed no systemic adverse effects or 
abnormality. These vaccines also induced high frequencies of BCG-specific INF-γ secreting 
lymphocytes, thereby highlighting the importance of the development of possible infant 
vaccines. The results indeed show that heterologous prime-boost effectively optimizes both 
humoral and T-cell immune responses. Despite these advantages, there are several issues to be 
addressed when using BCG as an antigen delivery system. 
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1.6.1. Disadvantages of using rBCG as a vaccine 
BCG is slow-growing and the cells tend to aggregate, thus making it difficult to manipulate in 
the laboratory. Prior exposure to live environmental mycobacteria primes the immune system 
against antigens shared with BCG. The resultant memory response results in accelerated 
clearance of rBCG upon vaccination, thus limiting its effect as a TB vaccine in areas with 
environmental mycobacteria (Demangel et al. 2005). Recombinant BCG expressing foreign 
antigens can also be unstable in vitro and in vivo (Cayabyab et al. 2009, Joseph et al. 2010) 
Increased incidences of disseminated BCG disease in HIV+ newborns has lead to urgent need for  
development of safer vaccines to replace BCG based vaccines. This has also lead to the 
recommendation of World Health Organisation against vaccination of HIV+ newborns with 
BCG (Hesseling et al. 2007, Hesseling et al. 2009, Nuttall et al. 2008). Several strategies have 
been implemented to increase the safety of such vaccines and these include generation of M. 
tuberculosis and BCG auxotrophic mutants as well as replication-limited organisms 
(Sambandamurthy et al. 2006, Tullius et al. 2008, Sampson et al. 2011).    
 
For instance, studies have shown that M. tuberculosis pantothenate auxotroph (panCD) was 
highly attenuated in severe combined immune-deficient (SCID) mice and in immunocompetent 
BALB/c mice. SCID mice infected with this auxotroph allowed significant and prolonged 
survival as compared to mice infected with either M. bovis BCG or virulent M. tuberculosis 
(Sambandamurthy et al. 2002). Similarly, M. bovis BCG Pasteur ∆panCD, a slow growing 
pantothenic auxotroph, was constructed as a double-deletion mutant of the panC and panD genes 
that are involved in the de novo biosynthesis of pantothenate (Bardarov et al. 2002, Tullius et al. 
2008). Hence Tullius et al. 2008 showed that rBCG (∆panCD) 30 (the pantothenic auxotroph 
that over-expresses M. tuberculosis antigen 85B) is more attenuated than BCG in SCID mice and 
provided similar protection to BCG in immunocompetent guinea pigs. Having shown such 
promise in animal models, such vaccine candidates may be usefull in humans, most especially 
immune-comprosed individuals and newborns.  
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1.6.2. Stability of rBCG vaccines  
Over-expression of foreign antigens in BCG is one of the factors that can limit rBCG vaccine 
stability. The choice of vectors also has an influence in antigen stability. Integrating vectors have 
been shown to be more stable than episomal vectors (Mederle et al. 2002). For instance, Stover 
et al. (1991) were unable to express HIV-1 gp120 under the constitutive promoter hsp60 
episomally, but the same product was successfully expressed from an integrating vector. Al-
Zarouni, Dale 2002 reported low level expression of β-lactamase in BCG as a result of deletions 
in the plasmids. Infrequent mutations of DNA that is integrated into the chromosome and low 
copy (one copy) number, which leads to reduction in foreign antigen expression, have 
contributed significantly to making the integrating vectors more stable. However, decrease in 
expression due to a single copy rather than 5 copies of standard episomal vectors may result in 
poor immune responses (Falk et al. 2000). For this reason, foreign antigens have often been 
expressed episomally (Bastos et al. 2002, Langermann et al. 1994). 
 
1.6.3. Plasmid shuttle vector features  
E. coli-mycobacterial shuttle vectors have been widely used for the delivery of foreign antigens. 
The level and timing of antigen expression, together with the type of antigen presentation and 
processing during an immune response are largely determined by the features of such vectors. 
Promoter elements and leader peptides are amongst these features as they regulate the level of 
expression and presentation pathway of expressed foreign antigen to the immune system.  
 
Pathways of antigen presentation and processing are determined by antigen localization. 
Antigens can be directed to various cell compartments; including the cytoplasm, extracellular 
matrix and cell membrane by the use of various leader peptides such as the 19kDa lipoprotein 
and alpha antigen signal sequences (Al-Zarouni, Dale 2002, Stover et al. 1993). These signal 
peptides often function in the protein translocation systems.   
1.6.4. Protein translocation systems in mycobacteria   
Many mature cellular proteins are found remote from their site of synthesis and therefore require 
translocation to various compartments of the cell for maturation and assumption of functionality.  
For this reason, proteins need specialized translocation systems. Such mechanisms include 
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amongst others the Sec-mediated (Osborne et al. 2005) and the Sec-independent twin-arginine-
specific translocation (Tat) systems (Zhang et al. 2009). 
 
1.6.4.1. Sec-mediated system 
 Sec-mediated system is responsible for translocation of newly synthesized proteins out of the 
cytosol across the membranes before they attain their mature structure and functionality 
(Osborne et al. 2005, den Blaauwen et al. 1997). This system comprises of SecB; a molecular 
chaperone dedicated to protein export, SecA; an ATPase that aids in translocation of protein into 
and across membrane and the heterotrimeric complex SecYEG, which constitutes a „channel‟ for 
protein movement. Initiation of translocation is powered by ATP and proteins are directed to the 
system by signal that lack sequence similarity, but share common physical-chemical structure 
(Rigel et al. 2009, Sargent et al. 1998).   The signal peptide is an approximately 24 amino acid 
sequence organized in a tripartite manner; a positively charged amino-terminus, a hydrophobic 
core region and a hydrophilic carboxy-terminal domain containing a recognition sequence for 
peptidase cleavage (Posey et al. 2006). Gram negative signal sequences are approximately 20 
amino acids long, while Gram positive bacteria as well as mycobacteria may possess signal 
peptides of length of up to 60 residues (Wiker et al. 2000).  
 
Mycobacteria lack the SecB chaperone and therefore utilize other cytosolic chaperones to 
translocate proteins (Fekkes et al. 1997).   Mycobacteria, in particular M. smegmatis and M. 
tuberculosis, have two SecA proteins (SecA1 and SecA2) (Braunstein et al. 2001). SecA1 is the 
„housekeepiung‟ protein, whereas SecA2 is the accessory secretory factor that aids in the ATP 
driven  secretion of superoxide dismutase (SodA) and catalase peroxidase (KatG), which in turn 
detoxify reactive oxygen and nitrogen species (Braunstein et al. 2003, Kurtz et al. 2006). This 
implies that SecA2 is functional in promoting early extracellular growth of M. tuberculosis in 
murine infection and inactivated macrophages. Studies using a secA2 mutant of M. tuberculosis 
indicated that this accessory secretory factor is essential in inhibition of both innate and adaptive 
immune responses, which is important for bacterial survival within the host and for its 
pathogenesis (Braunstein et al. 2003, Kurtz et al. 2006).  
1.6.4.2. TAT system  
Trimethylamine N-oxide (TMAO) reductase and dimethyl sulfoxide (DMSO) reductase; 
periplasmic and membrane-bound multi subunit enzymes respectively are translocated through 
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to the periplasmic space and membrane respectively via the Sec-independent twin-arginine-
specific translocation (TAT) system. These precursor enzymes are directed to the TAT system 
by a long peptide sequence (leader peptide) of consecutive, invariant arginine residues organized 
in a tripartite manner similar to that of the Sec signal sequence (Posey et al. 2006). Such 
translocation is via the trans-membrane proton electro-chemical gradient (Zhang et al. 2009, 
Sargent et al. 1998). This system serves to translocate mostly mature folded proteins and is a 
virulence determinant in some pathogenic bacteria such as Vibrio cholerae (Zhang et al. 2009). 
The TAT system has been widely studied in E. coli and is functionally as well as structurally 
related to the pH-dependent protein import pathway found in thylakoid membranes of plant 
chloroplasts (Berks et al. 2000). Co-factor carrier enzymes involved in respiratory pathways and 
photosynthetic electron transport chain are mainly translocated via the TAT pathway (Berks et 
al. 2000). The TAT system is encoded by the three genes; tatA, tatB and tatC.  
 
Posey et al. (2006) used the TorA-GFP reporter system to determine if mycobacteria posses the 
TAT system. Part of torA is a 150bp fragment, which has the TAT-dependant signal peptide as 
well as the first four amino acids of the mature protein (Posey et al. 2006). This group discovered 
that signal peptide coupled GFP expression was directed to the periphery of the cells as opposed 
to the cytoplamic localization of uncoupled GFP in M. smegmatis. It was also evident by 
individual disruption of tat genes that they were all essential in the TAT system. Furthermore, 
studies in both E.coli and M. smegmatis have shown that such disruptions have negative effects 
on physiology, including metabolism of specific substrates and colony morphology (Posey et al. 
2006, Braunstein et al. 2001, Ize et al. 2004, Ochsner et al. 2002). 
 
1.6.4.3. Snm/ESX-1 system  
Mycobacteria use the snm/ESX-1 translocation system as an equivalent to type I-V translocation 
systems. This system is used to translocate ESAT-6 (early secretory antigen, 6kDa) and CFP-10 
(culture filtrate protein, 10kDa) antigens in mycobacteria (Guinn et al. 2004, Stanley et al. 2003). 
This was shown by the loss of ability of mycobacteria to export ESAT-6 and CFP-10 antigens 
following disruption of individual genes (M. tuberculosis snm1/Rv3870, snm2/Rv3871 and 
snm4/Rv3877), suggesting that these genes encode for a secretion system (Guinn et al. 2004, 
Stanley et al. 2003). The homologs of these genes in M. smegmatis are Sm3866, Sm3869, 
Sm3882c and mycP1 (Converse, Cox 2005). In M. tuberculosis, Rv3870 interacts with Rv3871, 
which function as an ATPase.    
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It was postulated that both ESAT-6 and CFP-10 form a tight dimmer, which is translocated by 
Rv3871 to the transmembrane protein formed by Rv3870 and Rv3877, which make a cytosolic 
membrane-spanning pore (Stanley et al. 2003, Champion et al. 2006). Studies have also 
indicated that CFP-10 has a seven amino acid signal sequence on the C-terminus, necessary for 
targeting of the antigen dimers for secretion (Stanley et al. 2003). This unstructured signal 
peptide is in a form of a handle that allows for ESAT-6/CFP-10 dimer translocation by Rv3871 
(Champion et al. 2006). This system modulates early events such as control of macrophage 
cytokine response during M. tuberculosis infection.  
 
1.6.5. Characteristics and use of signal peptides  
In as much as amino terminal signal peptides show little homology apart from the cleavage site 
for signal peptidase, the interactions between these sequences and their receptors appear to be 
selective for their physical characteristics rather than the primary amino acid sequence (Chou, 
Gierasch 2005). There exist distinct domains in these sequences. The N-domain contains at least 
one arginine or lysine, which are not necessarily essential for protein export. This positively 
charged N-domain is associated with the translocation machinery and the negatively charged 
phospholipids with the lipid bilayer of the membrane during translocation. The α-helical 
conformation of the amino acids forms the H-domain, which is important for the signal peptide 
function (Chou, Gierasch 2005, Akita et al. 1990, Wehrl et al. 2000).  The centre of the 
hydrophobic domain has glycine and proline residues, which allow the signal peptide to form a 
hair pin loop that inserts into the membrane (Wehrl et al. 2000). Cleavage of the signal 
sequences by specific peptidases is enhanced by the helix breaking residues found at the end of 
the H-domain. Lastly the C-domain contains the recognition site for peptidases, which cleave the 
signal peptide from the mature protein during or just after translocation (Chou, Gierasch 2005, 
Akita et al. 1990, Wehrl et al. 2000, Horwich et al. 1985). Such leader peptides have been shown 
to independently transport proteins and the efficiency of pre-protein translocation is dependent 
on their properties (Chou, Gierasch 2005). They have therefore been used in various vaccine 
vectors to translocate foreign antigens thereby possibly enhancing vaccine immunogenicity 
(Badell et al. 2009, Henao-Tamayo et al. 2007, Tjalsma et al. 2000).  
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1.6.6. Examples of signal peptides 
1.6.6.1. The 19kDa signal sequence 
Recent studies and DNA analysis have shown that 19kDa lipoprotein sequences from both M. 
bovis and M. tuberculosis are identical and have 75% homology to Mycobacterium avium 
(Ashbridge et al. 1989, Collins et al. 1990, Huntley et al. 2005). Figure 1.1 shows the 19kDa 
DNA sequence and the corresponding amino acid sequence. Lipoproteins have conserved short 
amino acid sequences, which signal translocation of lipoproteins into the extracellular matrix 
(Badell et al. 2009, Henao-Tamayo et al. 2007, Tjalsma et al. 2000). Amongst a variety of these 
sequences is the 19kDa signal peptide that is responsible for the translocation of the 19kDa 
lipoprotein. Biochemical studies indicate that the 19kDa antigen undergoes post-translational 
acylation and glycosylation prior to lodging of the mature 19kDa lipoprotein protein into the cell 
membrane and these modifications have been shown to be essential in the modulation of innate 
immune responses in humans (Stewart et al. 2005, Wilkinson et al. 2009).  
++++++                          M     K       R       G       L      T       V      A       V       A      G      A       A I       L       V                       
AAAGGAGCACAGG GTG AAG CGT GG A CTG ACG GTC GCG GTA GCC GGA GCC GCC ATT CTG GTC 
A     G      L       S       G      C     S S N      K       S       T      T
GCA GGT CTT TCC GGA TGT TCA AGC AAC AAG TCG ACT ACA
 
Figure 1.1: DNA sequence and corresponding amino acid sequence of the 19kDa signal peptide and part of the 
19kDa lipoprotein. +++++ indicates the putative ribosome binding site. Italicized and bolded sequence corresponds 
to part of the 19kDa lipoprotein nucleic acid sequence. Red and blue depict the acylation and glycosylation sites on 
the protein respectively (Adapted from (Ashbridge et al. 1989).  
This lipoprotein has been shown to be immunodominat in both mice (Erb et al. 1998) and 
humans (Harris et al. 1993) and has been shown to stimulate CD4
+
 and CD8
+
 T-cell proliferation 
as well as production of cytokines such as IL2, IFN-γ and IL-12 (Stewart et al. 2005, Wilkinson 
et al. 2009, Brightbill et al. 1999). Furthermore, studies have shown that an increased proportion 
of antibodies against M. tuberculosis were specific to the 19kDa lipoprotein thus emphasizing its 
immunogenicity (Prestidge et al. 1995). Deletion of the 19kDa lipoprotein rendered M. 
tuberculosis unable to replicate in vivo (Wilkinson et al. 2009). However this mutant strain 
remained immunogenic and protected mice against aerosol challenge to a similar degree to a 
BCG vaccine. This mutant strain was well able to grow in vitro, but not in vivo (in 
macrophages), suggesting that the 19kDa lipoprotein may be pivotal in the host cell phagosome 
(Henao-Tamayo et al. 2007). Furthermore, evidence from confocal microscopy, electron 
microscopy and sub-cellular fractionation indicated that this lipoprotein is exported from the 
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phagosomes into the host cell within the first hour of phagocytosis of live mycobacteria 
(Neyrolles et al. 2001). 
1.6.6.2. The α-antigen signal sequence 
The α-antigen 85B (α-Ag85B) is a putative virulence factor that falls under a family of exported 
fribronectin-binding proteins. This family consists of Ag85A, Ag85B and Ag85C, of which 
Ag85A and B are the most prominent (Armitige et al. 2000). These antigens are encoded by 
fbpA, fbpB and fbpC respectively and the resultant proteins allow for the organisms to bind 
selectively to fibronectin and other extracellular matrix proteins thus enhancing virulence of 
these pathogens (Patti et al. 1994). This binding capability may be correlated to adherence and 
dissemination in tissue (Armitige et al. 2000). Studies have shown that the antigen 85 complex 
may be secreted as well as being present on the mycobacterial cell walls (Abou-Zeid et al. 1988, 
Peake et al. 1993, Rambukkana et al. 1992). These proteins transfer mycolic acids to α-ά-
trehalose monomycolate (TMM) thus forming α-ά-trehalose dimycolate (TDM) (Belisle et al. 
1997). 
 
Although genetically distinct, these proteins show sequence homology both intraspecially and 
interspecially. Studies have shown that Ag85B has three binding sites to fibronectin (Peake et al. 
1993). Genes encoding Ag85B, a 30kDa pr tein termed MBP59 or alpha antigen (α-Ag) have 
been isolated from many mycobacterial species such as M. leprae and M. bovis BCG as well as 
non-tuberculous mycobacteria (Matsuo et al. 1988). The α-Ag has been expressed in E. coli and 
was shown to be a 323amino acid protein, consisting of 40 amino acid residues proposed to 
encode a signal peptide together with 283 amino acids encoding the mature protein (Matsuo et 
al. 1988). Figure 1.2 shows the DNA sequence and the corresponding amino acid sequence of 
the α-Ag signal peptide.  
M T D V S R K Ile R A W G R R L M I G T A
ATG ACAGAC GTG AGC CGA AAG ATTCGA GCTTGG GGACGC CGATTG ATG ATC GGC ACGGCA
A A V V L P G L V G L A G G A A T A G A
GCG GCT GTAGTC CTT CCG GGC CTG GTG GGG CTT GCC GGC GGAGCG GCAACCGCG GGC GCG
 
Figure 1.2: DNA sequence and corresponding amino acid sequence of the α-Antigen signal peptide. Bolded and 
underlined codons indicate the signal peptidase recognition sequence; Ala-X-Ala (Matsuo et al. 1988) 
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
23 
 
1.6.7. Use of leader peptides to determine the types of immune responses elicited 
Leader sequences direct antigens to various compartments of the cells. Such peptides may lodge 
the protein in the membrane or may facilitate extracellular secretion of the antigens from the cell, 
subsequently influencing the type of immune response elicited by such vaccines. Both CD4
+
 and 
CD8
+
 T-cells have been associated with expression of foreign antigen fused to the 19kDa signal 
peptide, which directs the protein to the cell membrane, whereas only CD4
+ 
T-cell responses are 
correlated to secreted antigens fused to the α–antigen signal sequence (Grode et al. 2002). Grode 
et al. (2002) reported the differential induction of protective cell-mediated immunity elicited by 
different recombinant BCG strains expressing Listeria monocytogenes p60 antigen in secreted, 
cytosolic, or membrane-attached form. Both the membrane-linked lipoprotein and the secreted 
p60 antigens offered nearly equal protection from listeriosis, whereas cytosolic p60 failed to 
protect mice from disease. On the contrary, Dennehy et al. (2007) demonstrated that oral or 
intraperitoneal vaccination of mice with rBCG expressing the α antigen leader sequence and the 
mature α antigen fused to the rotavirus VP6 protein  from the 18 kDa antigen promoter were not 
protected against rotavirus. However, this group argued that lack of protection by this vaccine 
may be related to lack of secretion or, if secretion did occur, to the type and magnitude of 
immune response induced by the secreted protein. On the other hand, similar to Grode et al. 
2002, Dennehy et al. (2007) showed protection of mice from rotavirus infection following 
vaccination with BCG Pasteur containing either episomal or integrative vectors expressing the 
VP6 protein fused to the 19kDa antigen membrane-anchoring signal sequence. Himmelrich et al. 
2000 construced a number of different rBCG expressing secreted or membrane targeted or 
cytosolic forms of the MalE protein. They found that levels of expression of the secreted form of 
MalE were far higher than that of the cytosolic form even when expressed from the same 
promoter. In addition rBCG expressing the highest levels of secreted MalE induced stronger and 
more rapid immune responses suggesting there is a correlation between antigen expression levels 
and the induction of immune responses. These results therefore highlight the importance of the 
use of signal peptides in the expression levels and immunogenicity of antigens expressed by 
rBCG.  
 
1.6.8. Mycobacterial promoters 
For the development of an effective HIV vaccine based on mycobacterial vectors, use of defined 
mycobacterial promoters has been shown to be beneficial in driving foreign gene expression. 
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Activity of such promoters has been evaluated using reporter genes such as β-lactamase (Al-
Zarouni, Dale 2002), β-galactosidase (Dellagostin et al. 1995)and gfp (Zahrt, Deretic 2000), 
amongst others.  
 
Although there are exceptions, mycobacterial promoters generally function poorly in E. coli (Das 
Gupta et al. 1993).  To gain an insight into the divergence of mycobacterial promoters as 
compared to those of E. coli, Das Gupta et al. (1993) analyzed the activity of mycobacterial 
promoters in E. coli DH5α by isolating several promoters from M. tuberculosis H37Rv and M. 
smegmatis using a promoter selection vector that was constructed for the identification of 
promoter elements in a homologous environment. This vector consisted of a promoterless 
chloramphenicol acetyltransferase gene (CAT); a kanamycin resistance gene for positive 
selection in mycobacteria as well as extra-chromosomal origins of replication for E. coli and 
mycobacteria. Different plasmids (100 each) from both M. smegmatis and M. tuberculosis 
consisting of a variety of mycobacterial promoters fused to the promoter-less CAT gene were 
transformed into E. coli. This group discovered that only 12 plasmids containing M. smegmatis 
DNA conferred chloramphenicol resistance on E. coli. Furthermore, none of the promoter 
plasmids derived from M. tuberculosis conferred chloramphenicol resistance on E. coli. This 
implied that most of mycobacterial promoters were found to function poorly in E. coli. The 
hsp60 and mtrA promoters were used in this study and are reviewed in more detail in the 
following two sections. 
 
Constitutive expression from the hsp60 promoter results in high levels of expression of foreign 
antigen which can lead to protein toxicity and instability. For instance, attempts by Stover et al. 
1991 to clone the HIV env gene under the control of the hsp60 promoter using a mycobacterial 
plasmid vector were unsuccessful; suggesting that expression of this gene was toxic. Al-Zarouni, 
Dale (2002) found out that the hsp60 driven expression of β-lactamase was markedly low in 
rBCG. Plasmid integrity checks in E. coli indicated that approximately 95% of the plasmids 
contained deletions, which explained the low level expression of the reporter gene. Taken 
together, these studies do emphasize the deleterious effect of hsp60 promoter on the expression 
of some foreign genes in mycobacteria. This may pose a disadvantage relative to the 18 kDa 
antigen and mtrA promoters, which have lower activity during in vitro growth and are induced 
on infection of macrophages (Dellagostin et al. 1995), thus driving the expression of a foreign 
antigen at a time when the antigen could be exposed to the immune system. The 18kDa antigen 
and mtrA promoters have been widely used in E. coli-mycobacterium shuttle vectors.  
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1.6.9. The hsp60 promoter 
The Hsp60 protein belongs to a large family of heat shock proteins, induced at high levels under 
conditions of stress thereby allowing the bacteria to survive hostile environments. The 
mycobacterial hsp60 promoter has two transcriptional start sites in BCG, tsA and tsB (Stover et 
al. 1991, Dellagostin et al. 1995). Only tsA is recognized in M. smegmatis (Dellagostin et al. 
1995). This promoter shows high constitutive activity in mycobacterial cultures and in vivo. 
However, in M. avium, hsp60 driven expression showed low activity during exponential growth 
in standing culture, but a considerable increase in activity during late exponential to late 
stationary growth phases (Batoni et al. 1998).  
 
1.6.10. The mtrA promoter  
Two component signal transduction systems are a class of well documented ubiquitous bacterial 
regulatory elements associated with signal recognition and response regulation (Zahrt, Deretic 
2000). These systems are involved in regulation of transient adaptations, cellular functions, 
production of secondary metabolites and virulence, as well as disease progression determinants 
in case of pathogens. These are comprised of a membrane bound sensor kinase, which upon 
stimulus encounter, is phosphorylated at the histidine residue. The phophoryl group is then 
transferred to the cognate cytosolic response regulator, which initiates responses to stimuli (Via 
et al. 1996).  
 
One of the well characterized two component signal transduction systems is the sensor kinase, 
MtrB, and its cognate response regulator MtrA. Studies have shown that MtrA but not MtrB is 
essential for M. tuberculosis viability in vitro (Zahrt, Deretic 2000). This group found that the 
mtrA promoter was expressed differentially in M. tuberculosis and BCG during infection of 
macrophages. In BCG, mtrA promoter expression was low immediately after infection of 
macrophages, but by day 3 post infection, mtrA promoter activity was comparable to that of 
hsp60. On the contrary, in M. tuberculosis, mtrA promoter activity resulted in constitutive 
expression upon infection of macrophages. Via et al. (1996) also showed that the mtrA promoter 
was induced in BCG on infection of macrophages.  
 
The use of inducible mycobacterial promoters has been employed in the expression of HIV 
genes using BCG as a vector. This lowers the in vitro metabolic stress and subsequently allows 
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for induction of expression of rBCG genes only upon infection of macrophages, thus driving the 
expression of a foreign antigen at a time when the antigen could be exposed to the immune 
system. 
 
1.7. Codon optimization of foreign genes 
The level of foreign antigen expression may be partly influenced by codon usage. Williams et al. 
(1988) first evaluated the effect of codon optimization on heterologous protein expression in E. 
coli. This group showed that there was an 8-10 fold increase in synthetic codon optimized IL-2 
expression compared to the expression of native cDNA sequence driven by the trc promoter in 
E. coli JM101 cells. Therefore, to optimize expression levels, foreign antigen codons have been 
matched with those of their respective host to attain such levels. Kanekiyo et al. 2005 have 
evaluated the effect of codon optimization in rBCG vector-based vaccines. This group showed 
that there was a 40 fold increase in p24 expression levels in rBCG expressing codon optimized 
HIV-1 p24 as compared to non codon optimized p24. Mycobacterial genomes have a high G+C 
content (more than 60%), as opposed to the HIV genome, which has a high A+T content. This 
implies that if such genes were inserted into mycobacteria, there will be low expression levels of 
such genes. However, codon optimization counteracts this by lowering the A+T content in the 
HIV genes, thus increasing mRNA stability and translation efficiency following their insertion 
into BCG. This in turn increases the expression levels. Codon optimization has also been shown 
to reduce the risk of recombination in HIV infected individuals due to decreased sequence 
homology between the natural HIV viral genome and the codon optimized gene (Andre et al. 
1998). 
 
1.8. Aim 
The long-term aim of our research group is to construct stable rBCG expressing HIV-1 antigens 
as candidate vaccines. The aims of this study were: 
 To select a stable plasmid backbone for the construction of rBCG expressing HIV-1 Gag 
 To determine if BCG  codon optimization of the gag gene  impacted on the stability of 
the vaccine shuttle vectors 
 To compare the stability rBCG expressing HIV-1 gag under the control of different 
promoters and with different leader sequences 
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 To compare the immunogenicity of rBCG expressing HIV-1 gag under the control of 
different promoters and with different leader sequences in a mouse model. 
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CHAPTER 2: MATERIALS AND METHODS  
2.1 Study design  
The project was divided into three parts; 1) plasmid shuttle vector construction and mapping, 2) 
evaluation of stability in model organism M. smegmatis by colony sizes and growth patterns and 
3) preparation of rBCG vaccine stocks and analyses of rBCG vaccine immunogenicity in mice.   
 
2.2 Materials and general methods for the growth and culturing of 
Escherichia coli  
This section will detail the specific materials and methods employed in the application /use of E. 
coli in the study.  
 
2.2.1 E. coli strains, growth media and culture conditions 
E. coli DH5α and SCS110 cells were used in this study. E. coli recombinants were spread plated 
on 2YT agar (16g Tryptone, 10g Yeast extracts, 5g NaCl and 15g agar per litre of water) 
supplemented with with 25µg/ml of kanamycin [Sigma-Aldrich, SA] and incubated overnight at 
37
o
C. The resultant recombinant colonies were cultured in 2YT broth (16g Tryptone, 10g Yeast 
extracts and 5g NaCl per litre of water) supplemented with 25µg/ml of kanamycin or in Luria 
Bertani broth (10g Tryptone, 5g Yeast extracts and 5g NaCl per litre of water), supplemented 
with kanmycin for large scale plasmid isolations. The cultures were grown at 37
o
C overnight 
with vigorous shaking. Recombinant E. coli glycerol stocks were prepared after culturing in 2YT 
broth, cultures were re-suspended in sterile glycerol to a final concentration of 15% and stored at 
-80
o
C until needed for further studies.   
 
2.2.2 Preparation of competent E. coli cells 
E. coli competent cells were prepared using a modification of the dimethyl sulphur-oxide 
(DMSO) method by Chung, Miller (1988). A loop-full of a glycerol stock of E. coli cells was 
streaked onto a 2YT agar plate and incubated overnight at 37
o
C. A single colony was selected, 
inoculated into 5ml of 2YT broth and incubated at 37
o
C overnight with shaking to generate a 
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starter culture. The starter cultures was diluted 1/100 in 2YT broth and grown to early log phase 
(OD600 0.2 – 0.4). The cells were harvested by centrifugation at 5000 rpm for 5 minutes at 4
o
C, 
and then re-suspended in 10ml of ice-cold TSB (10% w/v PEG, 5% v/v DMSO, 10mM MgCl2, 
and 10mM MgSO4). The cells were held on ice for 10 minutes and either transformed 
immediately or stored in ice-cold sterile glycerol to a final concentration of 10% v/v in 100µl 
aliquots at -80
o
C.   
 
2.2.3 Transformation of E. coli with shuttle plasmid vectors 
The heat-shock procedure was followed as described by Sambrook et al. (1989), with some 
modifications, for transformation of E. coli competent cells with plasmid vectors. Plasmid DNA 
(approximately 10ng) or ligation reactions were gently mixed with 100µl of competent cells that 
were previously thawed on ice. The mix was incubated on ice for 10 minutes and then heat-
shocked in a 42
oC water bath for 2 minutes. 2YT broth (900μl) was added and the mixture was 
incubated at 37
o
C for 60 minutes to allow for the expression of the antibiotic marker. The 
transformation mix was plated onto 2YT agar containing the appropriate antibiotics and then 
incubated at 37
o
C overnight. 
 
2.2.4 Enzymatic reactions 
2.2.4.1 Agarose gel electrophoresis of DNA  
Plasmid DNA and DNA fragments were separated according to size using agarose gel 
electrophoresis. Agarose was prepared at a concentration of 0.8% (0.8g agarose per 100ml of 
buffer, with 0.025% ethidium bromide), in 1X TBE buffer (24.2g Tris, 2.75g Boric acid and 
10ml 0.5M EDTA, pH8.0). The method followed was adopted from Sambrook et al. (1989). A 
6X loading buffer [Fermentas, SA] was added to the DNA samples (at 1x final concentration) 
which were then loaded onto the agarose gel together with a 1kb DNA molecular weight marker 
[Promega, SA].  TBE buffer was used as the running buffer and 0.05% ethidium bromide was 
added to allow for visualisation of DNA samples over UV light. The gels were electrophoresed 
for 120 minutes at 60 to 120 V in standard gel cast trays (75mm x100mm or 155mm x 200mm) 
and for 15 minutes at 40V for slide gels (75mm x 50mm).  
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2.2.4.2 Restriction endonuclease digestion, DNA extraction and purification  
Restriction endonuclease digestion of plasmids was performed according to the manufacturer‟s 
instructions [Roche, SA Diagnostics or Fermentas, SA Life Sciences] in a final volume of 20µl, 
apart from the restriction endonuclease digestions performed for cloning purposes. For cloning 
purposes, 4μg of plasmid DNA was digested with 10 units of restriction enzyme and 4μl of 
buffer in a final volume of 40μl. Restriction enzyme digests were incubated at 37oC (unless 
otherwise specified) for 1 to 3 hours and stopped by the addition of 6X loading dye [Fermentas, 
SA]. Plasmid DNA was purified from reaction mixes using a Qiaquick Purification Kit [Qiagen, 
SA] and DNA fragments were purified from agarose gels using the Qiaquick Gel Extraction Kit 
[Qiagen, SA] according to the manufacturer‟s instructions. 
 
2.2.4.3 Blunting of restriction sites by T4 DNA polymerase 
Where necessary 5‟ and 3‟ DNA overhangs resulting from restriction endonuclease digestion 
were blunted by the use of T4 DNA polymerase [Roche, SA Diagnostics], which fills in the 
DNA template in a 5‟ – 3‟ direction and also nibbles back in a 3‟ - 5‟ direction. The latter 
process was employed to blunt the 3‟ overhangs on plasmids generated in this study. For 
blunting reactions, the plasmid DNA  purified from agarose gels was mixed with 10nM dNTP‟s, 
5U of T4 DNA polymerase and the appropriate volume of water to make up a final reaction 
volume of 50µl and incubated at 37
o
C for 8 minutes. The reaction was stopped by the addition of 
3µl of 0.5M EDTA and placed on ice. The reaction was then cleaned up with a Min-Elute 
Reaction Cleanup Kit [Qiagen, SA] according to the manufacturer‟s instructions. The final 
concentration of the DNA sample was confirmed by comparison to lambda DNA of known 
concentration following slide gel electrophoresis. 
 
2.2.4.4 DNA ligation  
Ligations were performed using T4 DNA ligase [Promega, SA] at ambient temperature for 4 to 5 
hours. Following blunting reactions and reaction clean ups, the remainder of the blunting 
reaction mix (linear plasmids) were ligated using 10U of T4 DNA ligase, 1X ligase buffer and 
water to make up the total volume of 12μl. 
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2.2.5 Small scale plasmid DNA isolation 
The plasmid DNA was isolated on a small scale as follows: A single colony was inoculated into 
800μl of 2YT broth containing the appropriate antibiotic and incubated at 37oC overnight. 
Reference plates were prepared simultaneously by stabbing each selected transformant onto a 
numbered grid on a 2YT agar plate containing the appropriate antibiotic. Small scale plasmid 
isolation was performed on the overnight cultures using the modified alkaline lysis method from 
Sambrook et al. (1989). The isolated plasmids were re-suspended in 50µl of High Pure Plasmid 
extraction Kit elution buffer (10mM Tris-HCl, pH 8.5) [Roche, SA]. 
2.2.6 Large scale plasmid isolation  
To perform large scale plasmid isolation, a single colony from the reference plate of 
transformants was inoculated into 100ml of LB broth containing the appropriate antibiotic and 
incubated at 37
o
C overnight with shaking. Large scale plasmid is lation was performed using 
Geno-pure Plasmid Midi Kits [Roche, SA Applied Science] according to the manufacturer‟s 
specifications. A Nanodrop
®
 ND-1000 Spectrophotometer was used to quantify the plasmid 
DNA. The machine was initialised using 2µl of distilled water, blanked with 2µl of HPLC water 
and the absorbance at A260 and A280 of the samples were recorded. The calculation of DNA 
concentration was based on the theory that 1OD is equivalent to 50µg/ml of double stranded 
DNA (Sambrook et al. 1989). Screening and selection process for candidate recombinant clones 
carrying the six recombinant plasmid shuttle vectors with or without the gag gene is outlined in 
Figure 2.1.  
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Recombinant E. coli   
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Sequencing of cloning junctions  Further RE mapping  
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Small scale plasmid isolation & restriction 
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Recombinant E. coli   
Plasmid construct  
Transformation  
Preparation of glycerol stocks   Large scale plasmid DNA isolation    
 
Figure 2.1: Schematic diagram of the screening and selection process for candidate recombinant clones 
2.3 Construction of E. coli/mycobacterial shuttle vectors 
The plasmids pEMαGag2(V3SV5)gp33-41 and pEMGag2(V3SV5)gp33-41 and 
pEM19Gag2(V3SV5)gp33-41 were kindly supplied by Dr Helen Stutz (University of Cape 
Town, South Africa). These plasmids were derived from pMV261 (Stover et al. 1991) which 
contains a kanamycin resistance gene, an E. coli plasmid origin of replication, a low copy 
number mycobacterial plasmid origin of replication and a transcriptional terminator downstream 
of an expression cassette. The expression cassette contains: the M. tuberculosis mtrA promoter 
for induction of antigen expression in the host; no leader sequence or either the M. tuberculosis 
19kDa or antigen 85B (α) signal sequences for export of antigen from the cell; an HIV-1 subtype 
C Gag (Du151) gene; the 10 amino acid V3 CTL epitope derived from the HIV-1 subtype B 
envelope protein; the paramyxo-virus derived SV5 monoclonal antibody tag and the gp33-41 
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epitope from Lymphocytic Choriomeningitis Virus (LCMV). The HIV-1 gag gene, V3, SV5 and 
gp33-41 epitope tags were codon optimized for optimal expression in mycobacteria. The 1689bp 
DNA fragment, containing the HIV-1 gag and the epitope tags, shown below in Figure 2.2, was 
designed to contain unique restriction enzyme sites for ease of cloning and was synthesized by 
GeneArt [Germany]. The V3 CTL tag is a CD8 T cell epitope and was included to allow the 
comparison of the cellular immunogenicity of the different proteins (Burgers et al. 2006). The 
SV5 tag is a B cell epitope that has been shown to react with a monoclonal antibody when fused 
to the C terminus of various proteins (Hanke et al. 1992). These tags were used to allow the 
different proteins used in this study to be tracked and compared with one another. The LCMV 
gp33-41 tag was included for the comparison of T cell responses between different vaccine 
vectors used in another study. 
HIV-1 Gag2 (1540 bp)
Gp33-41 epitope
TGA
ApaI
NarI/KasI/SfoIBamHI SspI
EcoRV PvuII
PstI
HpaI
P17 P24 P15
SnaBI
ClaI
V3-SV5 epitope
1
pEM Vector Backbone
4908bp
KanR
oriE
oriM
mtrA pr
Signal sequence
HpaI
NdeI
ApaI
 
Figure 2.2: The schematic diagram of the Gag expression cassette synthesized by GeneArt and the strategy for 
cloning into the pEM plasmid backbone to yield the three parental plasmids (pEMαGag2(V3SV5)gp33-41, 
pEM19Gag2(V3SV5)gp33-41 and pEMGag2(V3SV5)gp33-41). This figure was supplied by Dr Helen Stutz. 
 
Six plasmid shuttle vectors were constructed, from the three plasmids described above, to 
produce a combination of vectors with or without signal peptides and with or without the HIV-1 
gag.  
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2.3.1 Construction of 1
st
 phase plasmids 
Plasmids;  pEMGag2(V3SV5), pEM19Gag2(V3SV5) and pEMGag2(V3SV5) were constructed 
from plasmids: pEMGag2(V3SV5)gp33-41, pEM19Gag2(V3SV5)gp33-41 and 
pEMGag2(V3SV5)gp33-41 respectively by excising the gp33-41 epitope tag. This was done as 
the gp33-41 tag had been found to cause plasmid instability in recombinant BCG (personal 
communication with Dr Helen Stutz). In addition the tag was not required in this study.  
 
Plasmids pEMGag2(V3SV5)gp33-41, pEM19Gag2(V3SV5)gp33-41 and 
pEMGag2(V3SV5)gp33-41 were digested with PstI [Roche, SA]. Linear DNA fragments were 
isolated, following gel electrophoresis using the QIAGEN, SA Min-Elute Gel Extraction Kit 
[QIAGEN, SA] according to the manufacturer‟s instructions. The eluted DNA was digested with 
PvuII [Roche, SA] and the reaction was cleaned up using the QIAGEN, SA Min-Elute Reaction 
Clean up Kit [QIAGEN, SA] according to the manufacturer‟s instructions. The PstI 5‟ overhangs 
were then blunted using T4 DNA polymerase [Promega, SA] and the relative plasmid DNA loss 
was assessed by comparing the band intensities of the blunted and unblunted DNA fragments 
following electrophoresis using a slide gel. The remainder of the blunted DNA was ligated using 
T4 DNA ligase [Promega, SA]; thereafter half of the ligation mix was used to transform E. coli 
DH5α competent cells. Expression mixes were plated on 2YT agar containing kanamycin 
(25μg/ml) and potential positive recombinants screened for by restriction enzyme mapping of 
plasmid DNA that had been isolated by a small scaled DNA isolation process. Selected 
recombinants were picked off reference plates prepared during the small scale plasmid isolation, 
cultured in 100 ml Luria Bertani broth containing kanamycin (25μg/ml) overnight at 370C with 
shaking and plasmid DNA isolated using a Geno-pure Plasmid Midi Kit [Roche, SA Applied 
Science]. The plasmid DNA was quantified using a Nanodrop Spectrophotometer and subjected 
to further restriction endonuclease enzyme mapping. The PstI/PvuII cloning junctions were 
sequenced to confirm that the ligation reaction had generated in frame fusions using primers 
pFRF7 5‟-CGCAAGAAGGGCTGCTGG-3‟ and pEM R, 5‟- AGCAGACAGTTTTATTGTTC-
3‟. The sequencing reactions were done at Stellenbosch University Sequencing Facility [Western 
Cape, South Africa]. DNAMAN [Lynnon Biosoft, Canada] and Chromos v2.3 [Technelysium, 
Australia] software were used to analyze the sequences. 
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2.3.2 Construction of 2
nd
 phase plasmids 
Plasmids; pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) were constructed from the 
plasmids generated in the previous section: pEMGag2(V3SV5), pEM19Gag2(V3SV5) and 
pEMGag2(V3SV5) respectively. These plasmids were constructed by removing the HIV-1 gag 
gene. 
 
The plasmids were digested sequentially with SnaBI [Roche, SA Diagnostics] and EcoRV 
[Roche, SA Diagnostics]. These restriction endonuclease sites span the gag (1.5kb) and both 
generate blunt ends. The reaction mix was electrophoresed to separate the DNA fragments. The 
larger ~ 5kb fragment was isolated, gel purified and plasmid loss assessed, as described 
previously. The linear plasmid was then ligated using T4 DNA ligase in a total volume of 12μl, 
thereafter 5µl of the ligated product was transformed into E. coli DH5α competent cells as 
previously described. Screening and selection of candidate recombinant clones was then 
performed as described in the previous section. The SnaBI/EcoRV cloning junctions were 
sequenced to confirm that the ligation reaction had generated in frame fusions using primers; 
pCONEPI F 5‟- TGGCGAACTCCGTTGTAGTG-3‟ and pEM R, 5‟- 
AGCAGACAGTTTTATTGTTC-3‟. The sequencing reactions were done at Stellenbosch 
University Sequencing Facility [Western Cape, South Africa] and the sequences were analyzed 
as previously mentioned. 
 
2.4 Materials and methods for the growth and culturing of Mycobacteria 
This section will detail the specific materials and methods employed in the application /use of 
mycobacteria in the study. The plasmids used in this chapter were constructed as outlined in 
Section 2.3.  
 
2.4.1 Mycobacterial strains, growth media and culture conditions 
M. smegmatis mc
2
155 (obtained from the BioVac institute, Cape Town, S.A) was used in this 
study as a model organism since it is a fast growing mycobacterium. This strain was used to 
evaluate the stability of the six constructed shuttle vectors by colony size and growth patterns. M. 
bovis BCG Pasteur panCD mc26000 (BCG Pasteur ∆panCD), a pantothenic acid auxotroph 
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obtained from Dr. William Jacobs Jr. (Albert Einstein College of Medicine, New York) was also 
used in this study. The attenuated auxotroph has been shown to possess a superior safety profile 
in immunocompromised mice in comparison to the current BCG vaccine and therefore was 
better suited for use as the rBCG vaccine (Tullius et al. 2008).  
 
All mycobacterial strains were grown on selective Middlebrook 7H9 (MB7H9) [Difco
TM
, USA] 
with 0.025%v/v tyloxapol (Tyl) [Sigma-Aldrich, SA] and 10%v/v oleic-acid albumin dextrose 
complex (OADC) [BioLab] (MB7H9-OADC-Tyl) or Middlebrook 7H10 (MB7H10) [Difco
TM
, 
USA] with 10%v/v OADC (MB7H10-OADC). Since BCG Pasteur ∆panCD strain carried a 
hygromycin marked deletion of the panCD genes required for pantothenate biosynthesis, the 
propagation of this strain required the additional supplementation with 24µg/ml pantothenate as 
well as 25µg/ml hygromycin for positive selection.  
 
Mycobacterial starter cultures were generated by inoculation of a single colony from solid agar 
plates or an aliquot of a thawed (on ice) 10% glycerol stock stored at -80C, into 5ml of MB7H9-
OADC-Tyl. These starter cultures were incubated in 50ml conical sterile tubes [Sterilin, UK] 
standing at 37°C with loosened lids for approximately 2 days for M. smegmatis and 5 or more 
days for the BCG strains. The starter culture volumes were subsequently increased to 10ml with 
the same M7H9-OADC-Tyl media and further incubated at 37°C until an OD600 of 
approximately 0.5 was obtained. The 10ml starters were then used to inoculate 100ml of the 
same media in 1L Schott bottles. BCG cultures were first incubated standing for 48hours at 37°C 
with loosened lids before being placed on rollers until the required cell density was obtained, 
while M. smegmatis cultures were placed on rollers straight away.  
 
For determination of growth patterns, cultures were propagated as outlined above and OD600 
readings were recorded every 8 hours for M. smegmatis and every 24 hours for BCG Pasteur 
∆panCD on a spectrophotometer [Beckmann DU-40, USA] using cell density as an indicator of 
bacterial growth. For accuracy, cultures were diluted to read between OD600 0.1 and 0.5 where 
necessary. 
 
2.4.3 Preparation of electro-competent mycobacterial cells 
The two mycobacterial strains used in this project were made competent by methods described 
by Parish, Stoker (1998). After starter cultures were established, inoculums were propagated in 
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100ml of M7H9-TYL-OADC media in the absence of antibiotic selection, except for BCG 
Pasteur ∆panCD, which required culturing in the presence of Hygromycin B, and pantothenic 
acid as previously described to an OD600 of 0.8-1 units. The cells were harvested as follows; the 
cultures were divided into 25ml aliquots, placed in centrifuge tubes and placed on ice for 2hours. 
These were then centrifuged at 10000rpm for 10 minutes at 4
o
C, then re-suspended in 12ml ice-
cold sterile 10% glycerol and centrifuged again at 10000rpm for 10 minutes at 4
o
C. This step 
was repeated once more and the pellet was finally re-suspended in 1ml ice-cold sterile 10% 
glycerol, after which the tubes were pooled together and the electro-competent cells were 
aliquoted into 0.4ml aliquots in 1.5ml cryo-tubes and stored at -80
o
C.  
 
2.4.4 Electro-transformation of shuttle plasmid vectors into mycobacteria 
M. smegmatis and BCG Pasteur ∆panCD competent cells were tha ed on ice, centrifuged at 
4000rpm for 1 minute and gently re-suspended in 0.6ml sterile 10% glycerol and then placed on 
ice. Constructed and confirmed plasmid DNA at a concentration of 0.5-1µg in a 5µl volume of 
HPLC water was added to 50µl of competent cells and gently well mixed to ensure a 
homogenous solution. This was transferred into a pre-chilled, 0.1mm electro-poration cuvette 
[Bio-Rad], tapped on paper towel to bring contents to the bottom of the cuvette, and placed on 
ice for 1minute. The cuvette was wiped dry with paper towel, placed in the Gene Pulser 
[Biorad, SA] and pulsed at a voltage of 1.8kV, capacitance of 25µF and resistance of 1000. 
Time constants were noted and 1ml MB7H9-OADC-Tyl (supplemented with pantothenate for 
BCG Pasteur ∆panCD samples) was added immediately. The expression mix was incubated at 
37
o
C for 4hours for M. smegmatis or overnight for BCG Pasteur ∆panCD. Expression mixes 
were plated onto MB7H10-OADC agar plates containing 10µg/ml kanamycin. In case of BCG 
Pasteur ∆panCD, the medium was supplemented with 24µg/ml pantothenate and 25µg/ml 
hygromycin. The plates were inverted and incubated at 37
o
C for 3 to 4 days for M. smegmatis or 
3 to 4 weeks for BCG Pasteur ∆panCD, before the colonies could be visualised. Plasmid DNA 
(provided by Dr Helen Stutz) was used as a positive control and a no DNA sample served as a 
negative control for transformation. 
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2.4.5. Total protein extraction  
Recombinant mycobacterial colonies were cultured in liquid media as described in Section 2.4.1 
to yield recombinant cultures from which cell free extract was obtained. Total protein or cell free 
extract was prepared for determination of basal level HIV-1 Gag expression from M. smegmatis 
cultures using the HIV-1 p24 capture ELISA. The bead beating method of cell free extract is 
described in the next section. 
2.4.5.1 Bead beating method 
This is the mechanical method of extraction of total protein from mycobacterial cultures. It 
employs the use of 0.1mm silicon/zirconia beads [BioSpec] and the FastPrep machine [Bio 101] 
for mechanical disruption of the cell wall thus releasing the cell free extract. A 30ml culture was 
harvested by centrifugation at 4000rpm for 10 minutes at 4
o
C and then re-suspended in 2ml of 
phosphate buffered saline (PBS, pH7.4). A 1ml aliquot was stored in 15% glycerol at -80
o
C for 
use in plasmid integrity checks, while the other aliquot was transferred to a FastRNA tube [Bio 
101] containing 0.5g of 0.1mm silicon/zirconia beads. The samples were processed at setting 6 
for 20 seconds, followed by incubation on an ice-water slurry for 2 minutes to prevent the 
samples from overheating. This was repeated three times. The samples were then centrifuged at 
14000rpm, at room temperature for 10 minutes to pellet the cell wall debris. The supernatant 
(cell free extract) was recovered and placed in a new 1.5ml eppendorf
TM
 tube and further 
clarified by centrifugation. Three aliquots of approximately 240µl of the cell free extract were 
stored at -80
o
C. One of these aliquots was subjected to a standard DC-Biorad, SA protein 
quantification assay.  
 
2.4.6 Quantification of total protein from mycobacterial cultures 
Total protein was quantified following the modified Lowry method using the DC-Biorad, SA Kit 
[Biorad, SA] according to the manufacturer‟s instructions. Bovine Serum Albumin (BSA) 
[Roche, SA Diagnostics] was used as a standard.  
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2.5 Evaluation of vector fitness   
One way of evaluating vector fitness is by growth rates on solid medium of recombinant cultures 
as this is indicative of the relative „health‟ of the colonies. The more the recombinant antigen 
expressed, the greater the metabolic burden placed on the host cell, thus the slower the growth 
rates (the smaller the colony size) (Bourn et al. 2007, Griffin et al. 2009). However, this strategy 
may be relatively unreliable when used as a sole stability indicator as mycobacterial colonies 
tend to clump, thereby making it difficult to count and infer colony size (Parish, Stoker 1998). 
Therefore, growth rates on liquid medium were also used to evaluate vector fitness. Furthermore, 
care was taken to compare colony sizes between plates with similar cell counts since a high 
density of colony forming units may limit colony size. Due to its faster replication capability in 
relation to slow growing BCG strains, M. smegmatis was used as a model organism. Studies 
done in our laboratory have indicated that the higher the foreign antigen is expressed by the 
vector, the slower the growth rate of the mycobacterium harboring such a vector (Griffin et al. 
2009). This is due to the inverse correlation between metabolic burden and growth rate as 
mentioned earlier. To test for this, we evaluated the growth rates of recombinant M. smegmatis 
cultures harboring various shuttle vectors.   
 
2.5.1 Indication of vector fitness by growth rates on solid medium 
Plasmid DNA (0.5µg) was electroporated into the same batch of M. smegmatis competent cells 
as outlined in Section 2.4.4. The expression mix was incubated at 37
o
C for 4 hours, then plated 
(100µl, 200µl and remainder of mix) onto MB7H10-OADC agar plates containing 10μg/ml 
kanamycin and incubated at 37
o
C for 3 to 4 days. The resultant colonies were evaluated for 
growth rates by colony size. The resultant colonies from the same dilution of expression mix 
were compared in order to get an aproaximate evaluation of colony sizes. An arbitrary selected 
scale ranging from 1 to 5 asterisks indicating the relative sizes from smallest to largest was used 
to determine the sizes of the colonies. M. smegmatis transformants containing the control vector 
pCONEPI were assigned a score of 5 asterisks. The pCONEPI does not contain an expression 
cassette and therefore does not express Gag-V3SV5 antigen.   
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2.5.2 Indication of vector fitness by growth rates in liquid medium 
Cultures (100ml) of recombinant mycobacteria at starting 0.005 OD units were grown on rollers 
at 37
o
C. Absorbance readings (OD600nm) were taken at 8hr intervals until cultures reached 
stationary phase. Plasmid pCONEPI served as a plasmid control.  
2.6 Evaluation of plasmid stability  
One way of evaluating plasmid stability in vitro is by colony counts whereby cultures harbouring 
plasmid vectors are grown in the absence of antibiotic selection in liquid medium. These cultures 
are then plated onto both selective and non-selective medium to determine percentage loss of 
plasmid.  
 
Following growth of recombinant mycobacterial cultures in liquid medium for evaluation of 
vector fitness, the cultures were stored in 15% glycerol in 1ml aliquots at -80
o
C for use in 
evaluation of plasmid stability (this was done at the end of the growth curve, after 48 hours, 
where cultures were grown in medium without kanamycin). The 15% glycerol stocks were 
thawed at room temperature and then serially diluted in MB7H9-OADC-Tyl. The serial dilutions 
(100µl each) of glycerol stocks were then plated on selective and non-selective MB7H10-OADC 
agar plates and incubated at 37
o
C for 3-5 days.   
 
2.7. Evaluation of basal level expression of HIV-1 Gag by p24 capture ELISA 
assay 
HIV-1 Gag p24 assays were done to evaluate expression of HIV-1 Gag in recombinant M. 
smegmatis cultures. The cell free extract was collected as cultures reached OD600 readings 
ranging between 0.5 and 1. This was done by the bead beating method as previously described. 
One μg of the cell free extracts was sent to National Health Laboratory Service (NHLS) virology 
laboratories, Groote Schuur Hospital, Cape Town, South Africa for quantification of HIV-1 Gag 
p24 antigen. Gag p24 content in the extract was determined using the VIDAS HIV P24 II 
machine [bioMérieux, France], and the HIV Ag (Gag p24) kit [Roche, SA] with recombinant 
Gag p24 (donated by Robin Thomas) as a standard.    
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2.8. Preparation of rBCG vaccine stocks 
The rBCG vaccine stocks were prepared in order to evaluate their stability and to test their 
immunogenicity in mice. The cultures were grown in selective MB7H9-OADC-Tyl media, 
supplemented with pantothenic acid and hygromycin, to an OD600 of between 0.5 and 1. A 20 ml 
sample was removed for protein isolation. The remaining cells were pelleted, resuspended in 20 
ml resuspension buffer (10% glycerol (v/v), 0.025% v/v tyloxapol, 140 mM NaCl) and pelleted 
as before. The pellets were resuspended in 5 ml resuspension buffer and a sample was taken to 
determine the absorbance. Samples were then adjusted to a final OD600 of 10 using resuspension 
buffer, aliquoted and frozen at -80°C. Prior to vaccination aliquots were defrosted on ice, dose 
dilutions were made in resuspension buffer and the vaccines were passed through a 25 gauge 
needle 5 times. Vaccine doses were based on absorbance readings whereby one absorbance unit 
was taken to be equivalent to 1x10
7cfu/100μl bacteria, comparable to the estimate of (Stover et 
al. 1993).  
2.9 Evaluation of rBCG vaccine stability by restriction endonuclease mapping 
of isolated plasmid DNA  
A modification of the method used in the High Pure plasmid isolation Kit [Roche, SA] was used 
to isolate plasmid from the recombinant BCG cultures. Exactly 200µl of rBCG vaccine stock 
stored at 1x10
9
cfu/ml was thawed at ambient temperature following which the cells were 
harvested by centrifugation at 14000rpm for 5 minutes. The pellet was re-suspended in GTE 
buffer (50mM glucose, 25mM Tris-HCl, pH 8.0, 10mM EDTA) and 20mg/ml lysozyme and 
incubated at 37
o
C with mixing for 3 hours. Plasmid was then isolated according to the High Pure 
Plasmid Isolation Kit‟s instructions. A 50µl of elution buffer was used to elute DNA. The sample 
was left at RT for 5 minutes and DNA was collected by a 14000rpm centrifugation for 60 
seconds at room temperature. Five μl of eluted DNA was transformed into competent E. coli 
cells, while the remaining DNA was stored at -20
o
C.   
 
The plasmids isolated from rBCG cultures vaccine stocks (20 colonies per rBCG vaccine stock) 
were transformed into E. coli as the quantity and quality of plasmid DNA isolated directly from 
mycobacteria is usually too low for restriction enzyme mapping. Recombinant plasmids isolated 
from E. coli were mapped with restriction enzymes XbaI/KspAI (HpaI) to confirm their general 
structure. 
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2.10 Vaccination of BALB/c mice with the rBCG vaccines and SAAVI-MVA-
C 
The rBCG vaccines expressing HIV-1 Gag, with various signal sequences were prepared as 
described in Section 2.8 and subsequently tested for their immunogenicity in BALB/c mice. The 
vaccines, vaccination schedules and protocols are described in Tables 2.1 and 2.2 as well as 
Section 2.10 below. Female BALB/c mice were purchased from South Africa Vaccine Producers 
Pty Ltd (Johannesburg, South Africa). These were housed in groups of 5 in the Animal Unit 
(University of Cape Town, South Africa) for a minimum of 10 days before vaccinations to allow 
them to adapt to their environment. All the animal procedures were approved by the University 
of Cape Town Animal Ethics Committee (AEC), approval number AEC 07-017a.  
 
The mice were primed with the rBCG vaccine (1x10
7
 cfu/200µl resuspension medium) by intra-
peritoneal vaccination on day 0 and boosted with 1x10
4 
pfu/100µl of SAAVI MVA at day 28 by 
intra-muscular injection of half the dose (50ul) into each hind leg muscle. On day 40, the mice 
were killed by cervical dislocation without anaesthesia and mouse spleens were harvested for 
isolation of a single cell suspension of splenocytes prepared as described in Section 2.10.1. The 
vaccines used and the outline of the vaccination schedule are shown in Tables 2.1 and 2.2 
respectively. SAAVI MVA-C is the South African AIDS Vaccine Initiative Modified Vaccinia 
Akara that containes a fusion gene comprising of portions of the HIV-1 subtype C gag, reverse 
transriptase, tat and nef genes (grttnC) and the truncated (by removal of 124 amino acids from 
the cytoplasmic tail of gp160) HIV-1 subtype C Env (gp150) and the V3 loop CTL epitope from 
the HIV-1 subtype B envelope protein (Burgers et al. 2006). 
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 Table 2.1: Description of the vaccines used to vaccinate mice   
Vaccine 
code  
vaccine Description of plasmids  
BCG1  BCG Pasteur ∆panCD  [pEMαGag2V3SV5] shuttle vector;  mtrA promoter, α-signal sequence, 
codon-optimised gag and V3SV5 epitope tag  in a 
stable vector backbone 
BCG2  BCG Pasteur ∆panCD  [pEM19Gag2V3SV5] shuttle vector;  mtrA promoter, 19kDa-signal 
sequence, codon-optimised gag and V3SV5 epitope 
tag  in a stable vector backbone 
BCG3  BCG Pasteur ∆panCD  [pEMGag2V3SV5] shuttle vector;  mtrA promoter, no signal sequence, 
codon-optimised gag and V3SV5 epitope tag  in a 
stable vector backbone 
BCG4 BCG Pasteur ∆panCD  [pEM19Gag2V3SV5] 
HS 
Same as  pEM19Gag2V3SV5, used as a control 
vaccine (provided by Dr Helen Stutz)  
BCG 5  BCG Pasteur ∆panCD  [pCONEPI] empty shuttle vector backbone (control without gag 
and V3SV5 tag) 
MVA SAAVI-MVA Recombinant vaccinia virus expressing the HIV-1 
grttnC genes as well as gp150CT containing the 
BALB/c CD8+T-cell epitope at the 3` end. 
Table 2.2: The vaccination schedule 
Mouse group 
(# mice 
per group) 
Day 0 
Prime rBCG 10
7 
cfu/200μl (i.p.) 
Day 28  
Boost  SAAVI MVA-C 10
4
 pfu/100μl 
(i.m. 50μl each tibialis muscle) 
Day 40 
End of experiment 
1 (5) BCG 1 MVA Kill, remove spleens 
2 (5) BCG 2 MVA Kill, remove spleens 
3 (5) BCG 3 MVA Kill, remove spleens 
4 (5) BCG 4 MVA Kill, remove spleens 
5 (3) BCG 5 MVA Kill, remove spleens 
6 (5) - MVA Kill, remove spleens 
i.p: interperitoneal vaccination. i.m: intramascular vaccination.  
2.10.1 Preparation of Mouse splenocytes 
Mouse spleens were placed in 10ml RPMI 1640 [Gibco/Invitrogen, SA].The spleens were then 
poured into a sterile cell strainer, placed in a petri dish and meshed with a 2ml syringe rubber 
plunger. The cell strainer was washed with 10ml RPMI and the cell suspension was transferred 
to a 50ml tube. This splenocyte cell suspension was topped up to 50ml with RPMI and then 
centrifuged at 1500rpm for 5 minutes. The supernatant was discarded and the pellet was re-
suspended in 50ml RPMI. The suspension was washed twice with 30ml of RPMI (before 
centrifuging the cells at the last wash, any fibrin clots were removed using a Pasteur pipette). 
The supernatant was removed and the pellet re-suspended in a final volume of 50ml RPMI. The 
red blood cells (RBC) were lysed with 1ml of the RBC lysis buffer, the suspension was mixed 
gently, centrifuged as before and supernant removed. The RBC free splenocytes were then re-
suspended in 50ml RPMI. The cells were diluted 1:10 in Trypan Blue and Turks and counted in 
a 0.002mm
2
 Neubauer counting chamber [Superior, Germany]. The required number of cells for 
ELISPOT and FACS were removed and the procedures carried out as described below.  
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2.10.2 Fluorescence-activated cell sorting (FACS) analysis to determine cell 
population in mouse spleens 
FACS was done using antibodies to cell surface markers on the isolated splenocytes to determine 
the composition of T cells and B cells in the splenocyte population. Cell surface receptors were 
stained with a fluorescent antibody mix (CD3-APC, CD4-FITC, CD8-PerCP and CD19-PE). 
Blocking solution (25μl) (FACS Buffer, normal rat serum, normal mouse serum and 
CD16/CD32) was added into a tube containing 1x10
6
 splenocytes and mixed. The tubes were 
incubated on ice for 20 minutes. The cells were then washed with 1ml FACS Buffer (PBS 
containing 1% FCS and 0.1% NaN3) and centrifuged at 1500 rpm for 5 minutes. The supernatant 
was discarded and the pellet re-suspended in the residual (small amount of buffer left after 
centrifugation) FACS buffer. The fluorescent antibody mix (50µl) was added into the tubes and 
placed on ice for 30 minutes in the dark. The cells were washed once in 2ml of FACS buffer on 
ice and re-suspended in the residual volume of FACS Buffer. About 400µl of FACS buffer was 
added into tubes and acquired on FACS Caliber Multiple Auto Sampler flow cytometer [BD 
BioSciences, USA].  
2.10.3 Assessment of CD8 and CD4 T-cell responses in spleens 
IFN-γ and IL-2 enzyme-linked immunospot (ELISPOT) assays were used to determine the 
frequencies of antigen-specific T-cells in the spleen (Section 2.10.4). The following 
peptides/antigens (Table 2.3) were used as stimulants during the IFN-γ and IL-2 ELISPOT 
assays. 
Table 2.3: The stimulating peptides/antigens for the IFN-γ and IL-2 ELISPOT assays 
Stimulatory peptide  Amino acid sequence  Description  
No peptide - (Media only; background control) 
Irrelevant peptide  TYSTVALSSL Irrelevant amino acid sequence 
AMQM (Gag CD8) AMQMLKDTI HIV-1 p24 Gag (65-73) 
MRC13 (Gag CD4) NPPIPVGDIYKRWIILGLNK HIV-1 p24 Gag (121-140) 
MRC17 (Gag CD4) FRDYVDRFFKTLRAEQATQE HIV-1 p24 Gag (161-180) 
ConA  - (Positive control [Sigma, MO, USA]) 
 
2.10.4 Mouse IFN- and IL-2 ELISPOT assays 
ELISPOT assays to quantify Gag-specific IFN- and IL-2-producing mouse splenocytes was 
performed using an ELISPOT Set/Kit [BD Biosciences, USA] according to the manufacturer‟s 
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instructions. The 96 well plates [BD Biosciences, USA] were pre-wet with 35% ethanol 
(15µl/well) for 60 seconds, before coating with capture antibody; these were then washed three 
times with 200µl of PBS. To coat the plates, 100l of the diluted purified anti-mouse IFN-γ or 
IL-2 antibody solution was added into each well of the ELISPOT plates and these were covered 
with parafilm and incubated at 4
o
C overnight. The coating antibody was removed and the wells 
were washed once with 200 l/well of blocking solution (R10 medium containing RPMI 1640 
with Glutamax, 10% Penicillin-Streptomycin, 10% FBS, 0.001% 2-ME). Blocking solution (200 
l/well) was added into each well and plates were incubated for 2 hours at ambient temperature. 
  
While blocking, red blood cells (RBC) were lysed in the splenocyte suspension prior to use. Per 
spleen cell pellet, 1ml of RBC lysing buffer (0.15M NH4Cl. 10mM KHCO3, 0.1mM EDTA and 
distilled water [Sigma-Aldrich, SA]) was added at room temperature. The tube was gently 
shaken for 1 minute.  This was followed by addition of 45ml RPMI 1640 and centrifugation for 7 
minutes at 5 000rpm.  The medium was decanted and pellet re-suspended in fresh RPMI 1640 
with 10%FCS. The cells were counted and adjusted to a cell concentration of 5 x 10
6
 splenocytes 
/ml R10. Blocking solution was discarded from the wells of the ELISPOT plate. The following 
(100l per well) were then added to triplicate wells: medium to determine background 
responses; irrelevant peptide, peptide stimulants (V3CTL, AMQM, MRC13, MRC17) (Table 
2.3); BCG lysate (1.871g protein/ml BCG lysate) to determine responses to BCG and ConA 
(0.1g/ml ConA) as a positive control stimulant. Splenocytes were then added to each well 
(100µl containing 0.5x10
6
 splenocytes).  The plates were covered with aluminum foil and 
incubated at 37
o
C, 5% CO2, humidified incubator for 23-24 hours.  The well contents were 
decanted and wells were washed twice with 200l/well of deionized H2O (wells were allowed to 
soak for 3-5 minutes at each wash step). Wells were washed three times with wash buffer I (PBS, 
0.05% Tween 20) (the washes were programmed on the ELx50 Auto Strip Plate Washer [Analytic 
and Diagnostic Products, SA]). Excess wash buffer from the wells was removed by blotting the 
plate on a piece of paper towel. 
 
For detection purposes, Biotinylated anti IFN- or anti IL-2 detection antibody [BioCom 
Biotechnology, SA] was prepared in dilution buffer (PBS, 10% FBS) according to the 
manufacturers‟ instructions and 100 l was added into each well. The plates were incubated for 2 
hours at room temperature. Detection antibody solution was discarded from plates, and wells 
were washed three times with wash buffer I. Avidin-horseradish peroxidase (Avidin-HRP) 
[BioCom Biotechnology, SA] was diluted in dilution buffer as indicated by manufacturers and 
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100 l of this was added into each well. The plates were covered and incubated for 1 hour at 
room temperature. The avidin-HRP solution in each well was decanted and plates were washed 
three times with wash buffer I as before. Wells were then washed three times with wash buffer 
II. Vector Nova Red Substrate sk-4800 solution [Southern Cross Biotechnology, USA] (100 
l/well) was added. Spot development was monitored for 5 to 10 minutes in the dark; making 
sure not to allow spots to overdevelop, to prevent high background responses. The substrate 
reaction was stopped by washing wells with H2O (5 to 6 washes under a running cold water tap). 
The plastic tray under the plate was removed to facilitate air-drying at room temperature 
overnight. Plates were stored in a dry place in the dark until analysis. The plates were scanned 
using the CTL Immunospot ELISPOT Reader Analyzer [Cellular Technology Ltd, Europe]. The 
spot forming units were enumerated using the ImmunoSpot Software, version 3.2. The mean 
number of spots in triplicate wells was calculated and background spots were subtracted. The 
values were expressed as net antigen-specific IFN- spot forming units (net sfu) per million 
splenocytes.  
 
2.10.5 Validation of vaccination dose and rBCG recovery from mouse spleens 
The appropriate dilutions of rBCG vaccine stocks were plated on MB7H10-OADC-VitB5-Hygr 
with and without kanamycin to confirm that the correct doses had been used and that the 
vaccines were stable. Also following the mice sacrifice, the rBCG cells were recovered from the 
splenocytes. The splenocytes in 35ml RPMI 1640 left over from the ELISPOT assay were 
centrifuged at 1 200rpm for 10 minutes and re-suspended in 1ml of re-suspension buffer. These 
were then plated onto MB7H10-OADC-VitB5-Hygr plates with and without kanamycin (0.5ml 
of each group onto each 90mm petri dish). The petri dishes were then inverted, incubated at 37
o
C 
for 4 weeks. At the end of this period, the rBCG colonies were counted.  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
47 
 
CHAPTER 3: RESULTS 
3.1 Summary of results  
E. coli-mycobacterium shuttle vectors have been widely used for the delivery of foreign genes 
into BCG. Critical issues to be considered in developing such vectors include the choice of 
promoter; codon optimization of the foreign gene for expression in mycobacteria and the use of 
leader sequences to facilitate localization of the foreign antigen.  
 
The following steps achieved the aim of this study, which was to compare rBCG expressing 
HIV-1 gag under the control of different promoters and leader sequences. Firstly, the optimal 
vector backbone was selected based on colony sizes. Secondly, a series of shuttle vectors with 
differing features, were constructed in order to assess the effect of these features on vector 
“fitness” in vitro. These features include promoters (hsp60, psmcy and mtrA), signal peptides (α-
antigen and 19kDa signal peptides), codon optimization of HIV gag and its subsequent addition 
into the vector. The last section of the study focused on the preparation of BCG Pasteur ∆panCD 
vaccines with the best shuttle vectors based on vector stability. These vectors contained various 
leader peptides and their immunogencity was then assessed following vaccination of BALB/c 
mice. 
 
In this study, it was shown that the addition of various vector features such as leader sequences 
and codon optimized HIV-1 gag did not have an effect on vector stability. Furthermore, the use 
of leader peptides resulted in differential expression levels of Gag as shown by p24 assays and 
lastly the use of such peptides may also have influenced the immunogenicity of Gag. The flow 
diagram of the summary of what was done in the study as well as selection criteria for vectors to 
be used in the immunogenicity studies is shown in Figure 3.1 and Table 3.1, which also indicates 
which vectors were constructed and/or used in this study.    
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Figure 3.1: The flow diagram of the summary of what was done in the study as well as selection criteria for vectors 
to be used in the immunogenicity studies 
 
pEMGag2V3SV
5  
pEM19Gag2V3SV
5  
pEMαGag2V3SV
5  
Evaluation of expression levels by p24 assays (in M. smegmatis)   Highest p24 
expression levels    
pEMGag2V3SV
5  
pEM19Gag2V3SV
5  
pEMαGag2V3SV
5  
Most 
immunogenic in 
terms of V3CTL  
Evaluation of plasmid stability by restriction enzyme mapping 
(in pan BCG) and immunogenicity studies (in BALB/cmice) 
pEMαV3SV5  
pEM19V3SV5  
pEMV3SV5  
pEMαGag2V3SV5  
pEM19Gag2V3SV5  
pEMGag2V3SV5  
Indication of vector fitness and stability by 
restriction enzyme mapping and growth rates  
Constructs made  
(in E. coli) 
pEM19 pCB119 
 
hsp60 mtrA psmyc 
Choice of vector backbone by relative 
colony size (in M. smegmatis)   
Promoter selection  
(in M. smegmatis)   
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Table 3.1: Summary of the vectors constructed in the study and experiments carried out  
Name of construct  Features  Made 
in 
this 
study 
Plasmid 
checked 
by RE 
mapping  
Sequencing 
of cloning 
junctions  
Growth rates 
on media 
backbone 
fitness  
promoter Signal 
sequence 
V3SV5 Solid  Liquid  
pCB119Gag hsp60 19kDa None X X X √ √ N 
pEM19Gag mtrA 19kDa None X X X √ √ Y 
pCB119Gag1 hsp60 19kDa None X X X X √ X 
pEM19Gag1 mtrA 19kDa None X X X √ √ X 
pESDGag2V3SV5 psmyc None √ X X X √ X X 
pEHDGag2V3SV5 hsp60 None √ X X X √ X X 
pEMαGag2V3SV5 mtrA α √ √ √ √ √ X X 
pEM19Gag2V3SV5 mtrA 19kDa √ √ √ √ √ √ X 
pEMGag2V3SV5 mtrA None √ √ √ √ √ √ X 
pEMαV3SV5 mtrA α √ √ √ √ X X X 
pEM19V3SV5 mtrA 19kDa √ √ √ √ √ X X 
pEMV3SV5 mtrA None √ √ √ √ √ X X 
pF10 hsp60 None None X X X X X X 
pCONEPI None  None None X X X √ √ Y 
The constructs used in this study were with or without HIV-1 gag, where Gag: non-codon optimised, Gag1: first 
codon optimisation, Gag2: second codon optimisation. √: indicates what was done or feature present, while X: 
indicates what was not done and none: shows feature that was not present in vector.  N or Y: show lack of or vector 
fitness   
 
3.2 Development of stable vaccine shuttle vectors 
Instability of episomal vectors expressing foreign antigens in rBCG is often reported (Joseph et 
al. 2010). This may be due to the overexpression of foreign proteins, which are in some way 
toxic to mycobacteria. In BCG, foreign antigen can be expressed within the cell, secreted or 
linked to the mycobacterial cell membrane. Expression of high levels of foreign antigen in the 
cytoplasm of BCG could also result in instability of rBCG, thus the use of leader sequences 
targeting the antigen to the mycobacterial membrane or out of the cell maybe beneficial. The 
location of the foreign antigen may also determine the pathway by which the antigen is presented 
to the immune system. In this study a more stable shuttle vector was selected and the effect of 
the use of different leader peptides assessed in terms of vector fitness, antigen expression and 
immunogenicity. 
 
3.2.1 Selection of optimal shuttle vector  
Choice of stable vector backbones may also enhance expression of foreign antigens. In order to 
address this, the relative vector fitness of two E. coli/mycobacterial shuttle vectors pCB119Gag 
and pEM19Gag were compared in order to select the best vector in terms of its fitness as 
indicated by colony sizes. Both plasmids contain the M. tuberculosis mtrA promoter, the 19 kDa 
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leader sequence fused to the gag gene, E. coli and mycobacterial origins of replication and the 
aph gene which confers kanamcyin resistance. In addition pCB119Gag contains the lysA gene, 
which encodes meso-diaminopimelate decarboxylase, an enzyme catalyzing the last step in 
lysine biosynthesis, expressed from the hsp60 promoter. In our laboratory, it was discovered that 
the hsp60 expressed lysA gene, encoded on the original vector backbone (pCB119) and designed 
for selection in lysine auxotrophic strains, imposed additional metabolic stress resulting in 
slower growth rates and hence leading to vaccine instability. Therefore, to improve plasmid 
stability, the hsp60 promoter and the lysA gene were removed from the vector to generate 
plasmid pEM19Gag.  
 
The relative fitness of the two vectors was assessed by comparing the colony size of M. 
smegmatis transformed with plasmids pCB119Gag (8146bp) and pEM19Gag (6412bp). A scale 
was selected by means of asterisks (*), with pCONEPI transformants being assigned five 
asterisks (*****), as the largest colony size. The pCONEPI was used as an empty vector control 
in this study. It contains the E. coli and mycobacterial origins of replication and the aph gene 
which confers kanamcyin resistance but does not contain the mtrA promoter, 19 kDa leader 
sequences or the hsp60 promoter – lysA gene cassette. 
 
The recombinant M. smegmatis colonies harbouring pCB119Gag were very small as compared 
to M. smegmatis [pEM19Gag] colonies which were slightly larger and were assigned a score of 
two asterisks (Figure 3.2 and Table 3.2). These results indicated that the pCB119 vector 
backbone contributed to impaired recombinant mycobacterial fitness as compared to pEM19. 
The pEM19 vector backbone was therefore chosen as the better vector for all further studies. A 
more detailed vector fitness and stability assessment is shown in Section 3.2.3 
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pCB119Gag
pCONEPI
pEM19Gag
 
Figure 3.2: Determination of plasmid stability by recombinant M. smegmatis colony sizes. Comparison of M. 
smegmatis colonies harbouring the following plasmids; pEM19Gag; pCB119Gag and the positive control 
pCONEPI. 
 
Table 3.2: Determination of plasmid stability by comparison of recombinant M. smegmatis colony sizes. Relative 
colony size (RCS) was described using an arbitrary scoring system by means of asterisks ranging from * to *****, 
from smallest to largest. 
Plasmid RCS 
pEM19Gag *** 
pCB119Gag ** 
pCONEPI ***** 
 
3.2.2 Construction of plasmid shuttle vectors for rBCG-HIV vaccines 
Having selected the most “fit” episomal vector backbone; pEM19 in the previous section, we 
designed and constructed six vectors with the mtrA promoter, either the α signal sequence, the 
19kDa signal sequences or no signal sequence, with or without the HIV-1 gag and the V3SV5 
tag (pEMαGag2(V3SV5), pEM19Gag2(V3SV5), pEMGag2(V3SV5), pEMα(V3SV5), 
pEM19(V3SV5) and pEM(V3SV5)). Table 3.11 shows the features of these plasmid shuttle 
vectors. The in vitro stability of these vectors was evaluated by means of growth rates in the fast 
growing model organism M. smegmatis. Three of these were then selected in order to determine 
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the influence of the signal peptides on the immunogenicity of HIV-1 Gag antigen following 
vaccination of BALB/c mice with such rBCG vaccines.  
 
3.2.2.1 Construction of pEMGag2(V3SV5), pEM19Gag2(V3SV5) and pEM Gag2(V3SV5) 
In order to evaluate the effect of α and 19kDa signal peptides on vector fitness as well as their 
immunogenicity, we constructed three plasmids; pEMGag2(V3SV5), pEM19Gag2(V3SV5) and 
pEMGag2(V3SV5) from the following parental plasmids; pEMGag2(V3SV5)gp33-41, 
pEM19Gag2(V3SV5)gp33-41 and pEMGag2(V3SV5)gp33-41 respectively. The resultant 
constructs were similar to the parentals, but lacked the gp33-41 epitope, which was removed by a 
sequential restriction endonuclease digestion with PvuII and PstI restriction enzymes as 
mentioned in Section 2.3.1. Figure 3.3 shows schematic diagram of the cloning strategy 
employed in the construction of these vectors. 
  
Restriction endonuclease mapping with SspI and PstI confirmed that the plasmids were of 
correct sizes. SspI sites are located in the HIV-1 gag gene and also on kanamycin resistance gene 
3` downstream of the gp33-41, while PstI was lost during construction of the plasmids. 
Therefore no digestion of pEMGag2(V3SV5), pEM19Gag2(V3SV5) and pEMGag2(V3SV5) 
constructs with PstI endonuclease was expected. As seen in lanes 2 of Figures 3.4 to 3.6, the 
pEMGag2(V3SV5), pEM19Gag2(V3SV5) and pEMGag2(V3SV5) plasmid DNA digested with 
PstI had the same banding pattern as undigested  controls in lanes 3, indicating that the PstI site 
had been lost as expected. In contrast, the original plasmids still contained the PstI restriction site 
(lanes 4). As expected, a small difference in the size of the smaller DNA fragment (68bp) could 
be seen following digestion with restriction enzyme SspI (Table 3.3, Figures 3.4, 3.5 and 3.6, 
lanes 6 and 7). This showed that the constructed vectors were indeed of correct sizes and had lost 
the gp33-41 epitope as expected.  
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Figure 3.3: Schematic diagram of the cloning strategy employed in order to remove the gp33-41 tag from the three 
recombinant plasmid shuttle vectors containing the gag gene: pEMαGag2(V3SV5)gp33-41, 
pEM19Gag2(V3SV5)gp33-41 and pEMGag2(V3SV5)gp33-41. The gp33-41 tag is shown in green, following the 
V3SV5 tag (yellow). 
Blunting reaction 
Digestion with PvuII, reaction clean up 
Digestion with PstI (to generate overhangs), gel extraction and purification 
Ligation reaction 
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Figure 3.4: Restriction enzyme mapping of plasmid pEMαGag2(V3SV5) by digestion with PstI and SspI. Lanes 1 
and 8: 1kb DNA molecular weight marker; lane 2: pEMGag2(V3SV5) digested with PstI; lane 3: undigested 
pEMGag2(V3SV5) plasmid; lane 4: pEMGag2(V3SV5)gp33-41 plasmid control digested with PstI; lane 5: 
undigested pEMGag2(V3SV5)gp33-41; lane 6: pEMGag2(V3SV5) digested with SspI; lane 7: 
pEMGag2(V3SV5)gp33-41 digested with SspI.  
1       2       3      4       5        6       7       8      1        2       3       4        5       6       7        
8      
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Figure 3.5: Restriction enzyme mapping of pEM19Gag2(V3SV5)by digestion with PstI and SspI. Lanes 1 and 8: 1kb 
DNA molecular weight marker; lane 2: pEM19Gag2(V3SV5) digested with PstI; lane 3: undigested 
pEM19Gag2(V3SV5) plasmid; lane 4: pEM19Gag2(V3SV5)gp33-41 plasmid control digested with PstI; lane 5: 
undigested pEM19Gag2(V3SV5)gp33-41; lane 6: pEM19Gag2(V3SV5) digested with SspI; lane 7: 
pEM19Gag2(V3SV5)gp33-41 digested with SspI.  
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Figure 3.6: Restriction enzyme mapping of plasmid pEMGag2(V3SV5) by digestion with PstI and SspI. Lanes 1 and 
8: 1kb DNA molecular weight marker; lane 2: pEMGag2(V3SV5) digested with PstI; lane 3: undigested 
pEMGag2(V3SV5) plasmid; lane 4: pEMGag2(V3SV5)gp33-41 plasmid control digested with PstI; lane 5: 
undigested pEMGag2(V3SV5)gp33-41; lane 6: pEMGag2(V3SV5) digested with SspI; lane 7: 
pEMGag2(V3SV5)gp33-41 digested with SspI.  
 
Table 3.3: Expected fragment sizes (bp) resulting from restriction endonuclease digestion of the plasmid DNA 
Plasmid Name Expected fragment size 
SspI PstI 
pEMGag2(V3SV5)gp33-41 1148, 5414 6562 
pEM19Gag2(V3SV5) gp33-41 1148, 5423 6571 
 pEMGag2(V3SV5) gp33-41 1148, 5288 6436 
pEM Gag2(V3SV5) 1080, 5414 Uncut 
pEM19Gag2(V3SV5) 1080, 5423 Uncut 
pEMGag2(V3SV5) 1080, 5288 Uncut 
 
The plasmids were sequenced using the pCONEPI forward 5‟- 
TGGCGAACTCCGTTGTAGTG-3‟ and pEM reverse 5‟- AGCAGACAGTTTTATTGTTC-3‟ 
primers to confirm that the V3SV5 epitope-tag was in frame with the stop codon. The PvuII and 
PstI junctions were in frame with the stop codon in all the constructs. Having established that the 
constructs were of correct sizes by restriction endonuclease mapping and confirmed that the 
cloning junctions were in frame; these plasmids were subsequently used for generation of the last 
three constructs that lacked the HIV-1 gag gene.  
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3.2.2.2 Construction of pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) 
The last set of three plasmids pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) were 
constructed such that they lacked the HIV-1 gag gene, but still maintained the other features 
similar to the first three constructs. These constructs were to be used as negative controls, most 
especially during the evaluation of Gag expression by HIV-1 p24 assays. Figure 3.7 shows 
schematic diagram of the cloning strategy employed in the construction of these vectors.  
 
The following plasmids; pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) were constructed 
from; pEMGag2(V3SV5), pEM19Gag2(V3SV5) and pEMGag2(V3SV5) respectively by the 
removal of the HIV-1 gag following a sequential restriction endonuclease digestion with SnaBI 
and EcoRV as mentioned in Section 2.3.2. The restriction enzymes NcoI and EcoRV, which lie 
adjacent to gag gene were selected as suitable sites to confirm that the plasmids had indeed lost 
the 1.5 kb HIV-1 gag gene and were therefore of correct sizes. Plasmids digested with EcoRV 
and undigested plasmids; pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) were loaded in 
lanes 2 and 3 respectively. The similar banding pattern was observed in lanes 2 and 3 as 
plasmids pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) had lost the EcoRV site following 
the removal of gag gene as expected (Figure 3.8 to 3.10). This is as expected since all the three 
plasmids had lost the EcoRV site during their construction (lanes 3). As expected, a 1.5kb band 
difference of larger fragments in lanes 6 and 7 following digestion with NcoI indicated that the 
gag gene had been removed.    
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Figure 3.7: Schematic diagram of the cloning strategy employed for the construction recombinant plasmid shuttle 
vectors without the gag gene: pEMα(V3SV5), pEM19(V3SV5) and pEM(V3SV5). 
 
Digestion with EcoRV, reaction clean up 
Digestion with SnaBI, reaction clean up  
Ligation reaction 
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Table 3.4: Expected fragment sizes (bp) resulting from restriction endonuclease digestion of the plasmid DNA 
Plasmid Name Expected fragment size 
NcoI EcoRV 
pEMGag2(V3SV5) 1398, 5096 6494 
pEM19Gag2(V3SV5) 1398, 5105 6505 
pEMGag2(V3SV5) 1398, 4970 6398 
pEM(V3SV5) 1398, 3596 Uncut 
pEM19(V3SV5) 1398, 3605 Uncut 
 pEM(V3SV5) 1398, 3470 Uncut 
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Figure 3.8:  Restriction enzyme mapping of plasmid pEMα(V3SV5) by digestion with EcoRV and NcoI. Lanes 1 
and 8: 1kb DNA molecular weight marker; lane 2: pEM(V3SV5) digested with EcoRV; lane 3: undigested 
pEM(V3SV5) plasmid; lane 4: pEMGag2(V3SV5) plasmid control digested with EcoRV; lane 5: undigested 
pEMGag2(V3SV5); lane 6:  pEM(V3SV5) digested with NcoI; lane 7: pEMGag2(V3SV5) digested with NcoI. 
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Figure 3.9: Restriction enzyme mapping of plasmid pEM19(V3SV5) by digestion with EcoRV and NcoI. Lanes 1 
and 8: 1kb DNA molecular weight marker; lane 2: pEM19(V3SV5) digested with EcoRV; lane 3: undigested 
pEM19(V3SV5) plasmid; lane 4: pEM19Gag2(V3SV5) plasmid control digested with EcoRV; lane 5: undigested 
pEM19Gag2(V3SV5); lane 6:  pEM19(V3SV5) digested with NcoI; lane 7 pEM19Gag2(V3SV5) digested with NcoI.  
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Figure 3.10: Restriction enzyme mapping of plasmid pEM(V3SV5) by digestion with EcoRV and NcoI. Lanes 1 and 
8: 1kb DNA molecular weight marker; lane 2: pEM(V3SV5) digested with EcoRV; lane 3: undigested 
pEM(V3SV5) plasmid; lane 4: pEMGag2(V3SV5) plasmid control digested with EcoRV; lane 5: undigested 
pEMGag2(V3SV5); lane 6 pEM(V3SV5) digested with NcoI; lane 7: pEMGag2(V3SV5) digested with NcoI.  
 
To confirm that the cloning junctions were in frame with the V3SV5 epitope-tag and the stop 
codon, the plasmids were sequenced using the pCONEPI forward 5‟- 
TGGCGAACTCCGTTGTAGTG-3‟ and pEM reverse 5‟- AGCAGACAGTTTTATTGTTC-3‟ 
primers. Figure 3.11 shows the schematic summary of the expression cassettes cloned into the 
stable episomal plasmid vector backbone pEM. The resultant vectors were then evaluated for 
their fitness in vitro using M. smegmatis.  
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Figure 3.11: Schematic summary of the expression cassettes cloned into the stable episomal plasmid backbone pEM 
vector backbone. These vectors have various features such as the MtrA promoter, α or 19kDa signal sequences, with 
or without the HIV-1 gag and the V3 CTL-SV5 monoclonal tag. The figure also shows where these were derived. 
 
3.2.3 Determination of vector fitness by growth rates   
A large number of E. coli-mycobacterial shuttle vectors have been developed for the expression 
of foreign antigens in BCG. Key features of these vectors influence the stability as well as the 
extent and nature of the immune response that can be elicited by recombinant BCG. Promoter 
elements have received particular attention, as these regulate the level of expression of a foreign 
gene as a function of promoter strength and the timing of expression according to promoter 
activity. Other vector features that also influence expression levels include leader sequences used 
to target the protein within the BCG cell and inserted foreign DNA sequences (Langermann et al. 
1994, Himmelrich et al. 2000). These shuttle vector features influence stability of recombinant 
BCG antigen delivery systems.  
 
For this reason, we sought to evaluate shuttle vector fitness using M. smegmatis as a model 
organism due to its faster replication capability in relation to slow growing BCG strains. Thus as 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
61 
 
an indicator of vector fitness, M. smegmatis was transformed with equal quantities of the various 
shuttle vector constructs and colony sizes were compared to a control, M. smegmatis containing 
an empty plasmid backbone pCONEPI, (the smaller the colonies the more unstable the shuttle 
vector). Furthermore, care was taken to compare colony sizes between plates with similar cell 
counts since a high density of colony forming units may limit colony size. Cultures were also 
evaluated for stability by growth curves; whereby relative growth rates were compared.  
 
3.2.3.1. Indication of fitness by growth rates on solid medium 
The recombinant M. smegmatis cultures were generated by electro-poration of constructed 
plasmid shuttle vectors into electro-competent M. smegmatis cells. The cells were plated onto 
selective MB7H10-OADC agar plates. The resultant colonies were evaluated for vector fitness 
by relative colony sizes (RCS) after addition of various shuttle vector features. 
 
3.2.3.2 Selection of a suitable promoter (hsp60/psmyc vs mtrA) 
Promoters regulate the expression of foreign genes. Certain promoters are only induced upon an 
encounter with stimulus, while others constitutively express genes. The use of hsp60 promoter 
has been shown to result in high levels of constitutive transcription, which could, at times be 
deleterious to rBCG, whereas the mtrA promoter has low in vitro activity but is induced to 
similar levels to hsp60 in vivo (Zahrt, Deretic 2000). This allows for the expression of foreign 
antigen in rBCG at the time of exposure to the immune system.  
 
In this study, we sought to select the best promoter by electro-porating the following plasmids 
into M. smegmatis; pEMGag2(V3-SV5), pEHDGag2(V3-SV5), pESDGag2(V3-SV5), which have 
the M. tuberculosis  mtrA and hsp60 promoters , and M. smegmatis psmyc promoter respectively. 
The latter two constructs were kindly donated by Dr Ros Chapman (Unversity of Cape Town). 
The recombinant cells harbouring these plasmids were compared to the positive control 
pCONEPI by means of colony sizes. Figure 3.12 indicated that expression driven by the psmyc 
promoter (pESDGag2(V3-SV5)) resulted in poor vector fitness as no transformants were 
obtained. This experiment was repeated three times and the same results were obtained. The 
constitutive expression of gag by the hsp60 promoter (pEHDGag2(V3-SV5)) also resulted in 
very small pin prick size colonies, thus indicating lack of vector fitness. This could be due to 
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high levels of HIV-1 Gag expression, which appears to be toxic to mycobacteria. On the 
contrary, inducible expression by the mtrA promoter (pEMGag2(V3-SV5)) resulted in stable 
colonies, which were comparable to those harbouring pCONEPI. From these results, it is evident 
that high levels of constitutive expression driven by both the hsp60 and psmyc promoters 
contributed to reduced vector fitness in vitro as depicted by the small colony size scores of cells 
harbouring plasmids with such promoters or lack of transformants. In contrast, the inducible 
promoter (mtrA) enhanced vector fitness in vitro.   
pEMGag2(V3SV5)
pCONEPI
pESDGag2(V3SV5)
pEHDGag2(V3SV5)
 
Figure 3.12:  Evaluation of vector fitness following use of various promoters.Comparison of M. smegmatis colonies 
harbouring the following plasmids; pEMGag2(V3SV5); pEHDGag2(V3SV5); pESDGag2(V3SV5) and the control 
pCONEPI. The arrows indicate the pinprick colonies.  
 
Table 3.5: The relative colony size scores (RCS) of recombinant M. smegmatis colonies. RCS was assigned an 
arbitrary scoring system by means of asterisks ranging from * to *****, from smallest to largest. 
Plasmid RCS 
pEMGag2(V3SV5) **** 
pESDGag2(V3SV5) No colonies  
pEHDGag2(V3SV5) * 
pCONEPI ****** 
 
3.2.3.3 The use of leader peptides  
Leader sequences direct antigens to various compartments of the cells. Such peptides may lodge 
the protein in the membrane or may facilitate extracellular secretion of the antigens from the cell. 
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The colonies of M. smegmatis cells harbouring pEMαGag2(V3SV5), pEM19Gag2(V3SV5) and 
pEMGag2(V3SV5), which have the α-antigen signal sequence, the 19kDa signal peptide and no 
signal sequence respectively were compared to those harbouring an empty vector pCONEPI. 
There was no difference in the relative colony sizes of the M. smegmatis cells (Figure 3.13 and 
Table 3.6), thus indicating that the signal peptides had no effect on vector fitness. The colony 
sizes were comparable to M. smegmatis [pCONEPI] colonies (Figure 3.13). These results 
showed that the use of either α-antigen or 19kDa signal peptides did not reduce stability.  
pEMαGag2(V3-SV5) pEM19Gag2(V3-SV5)
pEMGag2(V3-SV5) pCONEPI
 
Figure 3.13: Evaluation of vector fitness following use of various leader peptides. Comparison of M. smegmatis 
colonies harbouring the following plasmids; pEMαGag2(V3SV5); pEM19Gag2(V3SV5); pEMGag2(V3SV5) and the 
positive control pCONEPI. 
 
Table 3.6: The relative colony size scores (RCS) of recombinant M. smegmatis colonies. RCS was assigned an 
arbitrary scoring system by means of asterisks ranging from * to *****, from smallest to largest. 
Plasmid RCS 
pEMαGag2(V3SV5) ***** 
pEM19Gag2(V3SV5) ***** 
pEMGag2(V3SV5) ***** 
pCONEPI ***** 
 
3.2.3.4 Effect of HIV-1 gag codon optimisation on vector fitness   
There has been a strong correlation between codon usage and the level of expression in highly 
expressed antigens (Kanekiyo et al. 2005). Therefore, in this study, we evaluated the effect of 
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codon optimisation on vector fitness using the following plasmids: pEM19Gag1 and pEM19Gag, 
which contain codon optimised and non-codon optimised HIV-1 gag respectively. There was a 
slight increase in colony size between M. smegmatis [pEM19Gag] (RCS = ***) and M. 
smegmatis [pEM19Gag1] (RCS of ****), indicating that codon optimisation may slightly 
improve relative vector fitness (Figure 3.14).  
pEM19Gag pEM19Gag1
pCONEPI
 
Figure 3.14: Comparison of M. smegmatis colonies harbouring the following plasmids; pEMαGag, pEM19Gag1 and 
the positive control pCONEPI. 
 
Table 3.7: The relative colony size scores (RCS) of recombinant M. smegmatis colonies. RCS was assigned an 
arbitrary scoring system by means of asterisks ranging from * to *****, from smallest to largest. 
Plasmid RCS 
pEM19Gag *** 
pEM19Gag1 **** 
pCONEPI ***** 
 
3.2.3.5 The effect of HIV-1 gag on vector fitness 
To evaluate the effect of addition of the codon optimised HIV gag on vector fitness, the M. 
smegmatis colonies harbouring pEM19Gag2(V3SV5), pEMGag2(V3SV5),  pEM19(V3SV5) and 
pEM(V3SV5) were compared. All the constructs were stable as shown by the high relative 
colony size scores (Figure 3.15), thus the addition of codon optimised gag did not have any 
effect on the relative vector fitness in vitro when expressed from the mtrA promoter.  
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pEMGag2(V3-SV5)
pEM (V3-SV5)
pEM19Gag2(V3-SV5)
pEM19(V3-SV5)
 
Figure 3.15: Evaluation of vector fitness following addition of codon optimised HIV-1 gag gene. Comparison of M. 
smegmatis colonies harbouring the following plasmids; pEM19Gag2(V3SV5), pEMGag2(V3SV5), pEM19(V3SV5) 
and pEM(V3SV5). 
 
Table 3.8: The relative colony size scores (RCS) of recombinant M. smegmatis colonies. RCS was assigned an 
arbitrary scoring system by means of asterisks ranging from * to *****, from smallest to largest. 
Plasmid RCS 
pEM19Gag2(V3SV5) **** 
pEMGag2(V3SV5) **** 
pEM19(V3SV5) **** 
pEM(V3SV5) **** 
 
In essence, change of plasmid backbone from pCB- to pEM- resulted in more “fit” recombinant 
mycobacteria. Furthermore, addition of the inducible mtrA promoter, leader sequences, and 
codon optimised gag as well as epitope-antibody tags did not interfere with the plasmid fitness.  
 
3.2.4 Indication of fitness by growth rates on liquid medium 
As mentioned earlier, one way of evaluating vector fitness is by growth rates of recombinant 
cultures on solid medium. However, this strategy may be relatively unreliable when used as a 
sole stability indicator as mycobacterial colonies tend to clump, thereby making it difficult to 
count and infer colony size. Therefore, growth rates in liquid medium were also used to evaluate 
vector fitness. When grown in selective medium, cultures may exhibit faster growth rates due to 
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vector stability. To test for this, the growth rates of recombinant M. smegmatis cultures 
harbouring various vectors were evaluated. These cultures were grown in selective and non-
selective MB7H9-OADC-Tyl medium and the growth rates of these cultures were evaluated by 
monitoring the OD600 readings every 8 hours (every second doubling time for M. smegmatis) for 
a period of up to 48 hours (Figure 3.16). 
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Figure 3.16A: Growth curves of rM. smegmatis cultures grown in the presence of kanamycin 
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Figure 3.16B: Growth curves of rM. smegmatis cultures grown in the absence of kanamycin 
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Both the M. smegmatis [pEMGag2(V3SV5)] and M. smegmatis [pEM19Gag1] cultures grew 
faster than all the other cultures, when grown in media containing kanamycin. This is evident by 
their short lag phases and the fast exponential growth. On the other hand, M. smegmatis 
[pEM19Gag2(V3SV5)] and M. smegmatis [pCB119Gag1]  showed intermediate exponential 
growth rates, whereas M. smegmatis [pEM19Gag]  and M. smegmatis [pCB119Gag] were the 
slowest growing cultures (Figure 3.16A). When grown in non-selective medium (without 
kanamycin), all the cultures harbouring vectors with the codon optimised gag showed the faster 
exponential growth as compared to both non-codon optimised M. smegmatis [pCB119Gag] and 
M. smegmatis [pEM19Gag] cultures (Figure 3.16B).  
 
3.2.5 Evaluation of plasmid stability  
One way of evaluating plasmid stability in vitro is by colony counts whereby cultures harbouring 
plasmid vectors are grown in the absence of antibiotic selection in liquid medium (Section 3.2.4). 
These cultures are then plated onto both selective and non-selective medium to determine 
percentage loss of plasmid. In this study, plasmid stability was evaluated in the similar manner 
using duplicate cultures of rM. smegmatis. 
 
Table 3.9: The plasmid stability evaluation by colony counts following culturing in the absence of selection  
Plasmid transformed  With kanamycin  Without kanamycin  % plasmid 
loss Average number 
of colonies 
SD  Average 
number of 
colonies 
SD 
pCB119Gag1 163.5 20.5  133 5.6 0 
pEM19Gag1 155 25.5  142 45.3 0 
pCB119Gag 127 9.9  276.5 50.2 54 
pEM19Gag 211 15.6  230.5 33.2 8 
pEM19Gag2(V3SV5) 137.5 27.6  115.5 17.7 0 
pEMGag2(V3SV5) 94 21.2  106 21.1 11 
pCONEPI 98 5.6  98.5 2.1 0.5 
Gag: non-codon optimised, Gag1: first codon optimisation, Gag2: second codon optimisation. SD: standard 
deviation 
 
The M. smegmatis [pEM19gag1], M. smegmatis [pCB119Gag1] M. smegmatis 
[pEM19Gag2(V3SV5)] and M. smegmatis [pCONEPI] cultures showed no plasmid loss, whereas 
M. smegmatis [pCB119Gag] culture (culture with pCB119 backbone) experienced 54% plasmid 
loss. To note the M. smegmatis [pEMGag2(V3SV5)] and M. smegmatis [pEM19Gag] cultures 
had 11% and 8% plasmid loss, which was a not a great loss as compared to 54% loss, therefore 
indicating that the plasmids were also stable. These results indicate that generally codon 
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optimisation of genes contributes to plasmid stability to a certain degree, whereas vector 
backbone has a significant effect on vector fitness. 
 
3.3. Basal level expression of Gag from recombinant M. smegmatis  
HIV-1 Gag p24 assays were done to evaluate expression of HIV-1 Gag in recombinant M. 
smegmatis cultures harbouring plasmids with different leader peptides. This was done by the use 
of p24 capture Enzyme-Linked Immunosorbant Assay (ELISA). The cell free extract was 
collected as cultures reached OD600 readings of approximately 1. This was harvested by bead 
beating method. Approximately 1µg of the cell free extract in HPLC water was analysed. 
 
M. smegmatis transformed with pEMGag2(V3SV5) seamed to express more Gag as compared 
to M. smegmatis  [pEM19Gag2(V3SV5)] and M. smegmatis  [pEMGag2(V3SV5)] (64pg/ml as 
compared to 39 and 17 respectively). As expected, the three recombinants harbouring vectors 
without the gag showed no Gag expression. The <12pg/ml value reflects the background as 
observed with the negative control M. smegmatis [pCONEPI]. The three recombinants 
expressing gag from the inducible mtrA promoter expressed far lower levels of p24 in vitro as 
compared to the recombinant expressing gag from the constitutive hsp60 promoter; M. 
smegmatis [pF10]). There was a clear difference in p24 expression levels. The expression levels 
of both the constitutive and inducible expressers were comparable only when the former was at a 
tenfold lower concentration. These results indeed showed that the Gag expression levels were 
low during in vitro growth when the mtrA promoter was used. Table 3.10 below summarises the 
findings from this part of the study. The next part of the study was to prepare rBCG vaccine 
stocks and to evaluate their immunogenicity following vaccination of BALB/c mice.  
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Table 3.10: Summary of the evaluation of vector fitness and stability in the model organism M. smegmatis by means 
of relative colony sizes and growth rates 
Name of construct Evaluation of Vector fitness  Stability after 10 
generations 
HIV-1 Gag p24 
expression 
Colony size Growth rate in liquid media 
pEMGag2(V3SV5) ** X Stable 69.7 
pEM19Gag2(V3SV5) ** Intermediate Stable 39.4 
pEMGag2(V3SV5) *** Fast Stable 17.4 
pEM(V3SV5) X X X <12 
pEM19(V3SV5) ** X X <12 
pEM(V3SV5) *** X X <12 
pCONEPI **** Fast Stable <12 
pF10 X X X >400 
*: depicts the relative colony sizes, X: indicates what was not done on the vector.  
3.4 Recombinant BCG Pasteur ∆panCD vaccine stock preparation and 
stability checks by restriction enzyme mapping 
These results show that removal of hsp60-lysA, addition of signal peptides, codon optimisation 
of gag for expression in mycobacteria as well as use of inducible mtrA promoter for controlled 
expression of gag improve the relative vector fitness. Thus shuttle vectors containing the pEM 
backbone, codon optimised gag and mtrA promoter were chosen for further studies in BCG. 
Table 3.11 shows the constructs used in this part of the study as well as which vectors were 
chosen for immunogenicity studies.  
Table 3.11: Summary of the vectors constructed in the study and experiments carried out  
Name of construct  Features rBCG 
vaccine 
stock 
Evaluation of stability by 
RE mapping  
Vaccination 
of BALB/c 
mice promoter Signal 
sequence 
V3SV5 
pEM Gag2(V3SV5) mtrA α √ √ √ √ 
pEM19Gag2(V3SV5) mtrA 19kDa √ √ √ 
√ 
√ 
pEM Gag2(V3SV5) mtrA None √ √ √ 
pEM (V3SV5) mtrA α √ √ √ X 
pEM19(V3SV5) mtrA 19kDa √ √ √ X 
pEM(V3SV5) mtrA None √ √ √ X 
pCONEPI None None None  √ X √ 
The constructs used in this study were with or without HIV-1 gag, where Gag: non-codon optimised, Gag1: first 
codon optimisation, Gag2: second codon optimisation. √: indicates what was done or feature present, while X: 
indicates what was not done and none: shows feature that was not present in vector.  
 
To assess the effect of fusing different leader sequences to HIV-1 Gag on the immunogenicity of 
our recombinant BCG Pasteur ∆panCD vaccines stocks, the following vaccines were prepared: 
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BCG Pasteur ∆panCD [pEMαGag2V3SV5], BCG Pasteur ∆panCD [pEM19Gag2V3Sv5] and 
BCG Pasteur ∆panCD [pEMGag2V3SV5]. 
 
Studies have shown that M. tuberculosis pantothenate auxotroph (∆panCD) was highly 
attenuated in severe combined immune-deficient (SCID) mice and in immunocompetent 
BALB/c mice. This auxotroph allowed significant and prolonged survival of SCID mice than 
mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis 
(Sambandamurthy et al. 2002). Pantothenic acid (vitamin B5) is an essential molecule required 
for the synthesis of coenzyme A and acyl carrier protein (ACP), that play important roles as acyl-
group carriers in fatty-acid metabolism, the tricarboxylic-acid cycle, biosynthesis of polyketides 
and several other metabolic reactions. Similarly, M. bovis BCG Pasteur ∆panCD a slow growing 
pantothenic auxotroph was constructed as a double-deletion mutant of M. tuberculosis in the 
panC and panD genes that are involved in the de novo biosynthesis of pantothenate (Bardarov et 
al. 2002, Tullius et al. 2008). Tullius et al. (2008) showed that rBCG (∆panCD) 30 (the 
pantothenic auxotroph that over-expresses M. tuberculosis antigen 85B) is more attenuated than 
BCG in SCID mice and provided similar protection to BCG in immunocompetent guinea pigs. 
 
To confirm that the BCG Pasteur ∆panCD vaccine stocks were stable before vaccination of mice, 
plasmid DNA was isolated from the rBCG vaccine stocks. The plasmid DNA was then 
transformed into E. coli and plasmid DNA again extracted and then mapped using restriction 
endonucleases; XbaI and KspAI (HpaI). The plasmid DNA was transformed into E. coli and re-
isolated as the yield of plasmid DNA from mycobacteria is very poor. All plasmid DNA isolated 
from the BCG vaccine stocks showed expected banding patterns following restriction 
endonuclease digestion (Table 3.12, Figures 3.17 to 3.19). 
 
Prior to vaccination of BALB/c mice with the rBCG vaccines, sequencing of plasmids 
(pEMαGag2(V3SV5), pEM19Gag2(V3SV5) and pEMGag2(V3SV5) from these vaccines was 
done to further confirm that these vaccines were stable.  Large scale plasmid isolation was 
performed and 100ng/µl of the resultant plasmids was sent for sequencing at Stellenbosch 
University, Western Cape, South Africa. The entire 1687 fragment (GeneArt codon optimised) 
was sequenced and all the plasmids had no deletions, indicating that they were stable (data not 
shown).  This implied that all the vaccine stocks were 100% stable. Following these experiments, 
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these r BCG Pasteur ∆panCD vaccines were then used to vaccinate mice in order to evaluate 
their immunogenicity.   
 
Table 3.12: The expected number and sizes of DNA fragments following double digestion of plasmid DNA with 
XbaI and KspAI 
Plasmid  Expected no. of bands Expected band sizes in bp 
pEM Gag2(V3SV5) 2 4006, 2488 
pEM19Gag2(V3SV5) 2 4046, 2457 
pEM Gag2(V3SV5) 2 4046, 2322 
 
1        2          3          4          5        6         7         8         9        10        11        12       13    14 
1        2          3          4          5        6         7         8         9        10        11        12       13    14 
4006 bp
2488 bp
4006 bp
2488 bp
A
B
  
Figure 3.17: Restriction enzyme mapping of pEMαGag2(V3SV5) plasmid DNA isolated from BCG vaccine stocks. 
Plasmid DNA was digested with restriction enzymes XbaI and KspAI (HpaI). A & B: Lanes 1 and 14: positive 
control, original, untransformed DNA; lanes 2 – 4, 6 – 9 and 11 -13: plasmid DNA isolated from BCG vaccine 
stocks; lanes 5 and 10: 1kb DNA molecular weight marker. 
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1        2          3          4          5        6         7         8         9        10        11        12       13    14 
1        2          3          4          5        6         7         8         9        10        11        12       13    14 
4046 bp
2457 bp
4046 bp
2457 bp
A
B
 
Figure 3.18: Restriction enzyme mapping of pEM19Gag2(V3SV5) plasmid DNA isolated from BCG vaccine stocks. 
Plasmid DNA was digested with restriction enzymes XbaI and KspAI (HpaI). A & B: Lanes 1 and 14: positive 
control, original, untransformed DNA; lanes 2 – 4, 6 – 9 and 11 -13: plasmid DNA isolated from BCG vaccine 
stocks; lanes 5 and 10: 1kb DNA molecular weight marker. 
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1        2          3          4          5        6         7         8         9        10        11        12       13    14 
1        2          3          4          5        6         7         8         9        10        11        12       13    14 
4046 bp
2322 bp
4046 bp
2322 bp
A
B
 
Figure 3.19: Restriction enzyme mapping of pEMGag2(V3SV5) plasmid DNA isolated from BCG vaccine stocks. 
Plasmid DNA was digested with restriction enzymes XbaI and KspAI (HpaI). A & B: Lanes 1 and 14: positive 
control, original, untransformed DNA; lanes 2 – 4, 6 – 9 and 11 -13: plasmid DNA isolated from BCG vaccine 
stocks; lanes 5 and 10: 1kb DNA molecular weight marker. 
 
3.5. Immunogenicity of rBCG vaccines  
3.5.1 Immunogenicity of HIV-1 Gag 
The immunogenicity of HIV Gag is briefly reviewed in the following section and indicates the 
justification of the use of Gag in this study as a model HIV antigen. As viral set point after 
infection predicts disease progression, an effective vaccine should elicit strong immune 
responses to lower steady-state viral load upon infection (Manrique et al. 2008, Manrique et al. 
2009, Sircar et al. 2010, Valor et al. 2008).  One of the main strategies for HIV vaccines is the 
induction of a CTL immune response to highly conserved or cross-reactive epitopes of structural 
proteins such as Gag (Falk et al. 2000). Kanekiyo et al. (2005) demonstrated that rBCG 
expressing codon optimized HIV Gag p24 antigen was capable of inducing strong long-lasting 
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cell mediated immune responses even at low vaccine doses.  Honeyborne et al. (2007) analyzed 
the role of HLA-B*13 restricted Gag epitopes, which is associated with low viral load in HIV 
infection. The group discovered that HLA-B*13 positive individuals had low viremia as opposed 
to HLA-B*13 negative participants, who had high viral loads. The group also showed that, of the 
Gag peptides targeted, only the p24 Gag specific CD8
+
 T-cell responses were significantly 
associated with decreasing viral loads. On the contrary, Env or accessory protein-specific CD8+ 
T-cell responses were associated with increased viral loads (Kiepiela et al. 2007, Novitsky et al. 
2003). These results collectively show the strong correlation between increasing Gag-specific 
immune responses and decreased viral load. 
 
3.5.2 Immunogenicity of rBCG vaccines using a prime-boost vaccination regimen 
Heterologous prime-boost vaccination regimens employing bacteria and viruses as vectors 
delivering common T cell based immunongens induce stronger responses than multiple repeated 
dosing with homologous vaccine modalities (Rerks-Ngarm et al. 2009). HIV candidate vaccines 
have been shown in pre-clinical and clinical trials to induce better immune responses when used 
in prime - boost regimens (Paris et al. 2010, Brown et al. 2010). Support for use of prime-boost 
vaccination regimens was achieved with the results from the RV144 trial, a phase 3 efficacy trial 
conducted in 2009 in Thailand. Modest protection from HIV infection was achieved with this 
trial that evaluated a prime with a recombinant canary poxvirus vector vaccine (ALVAC-HIV 
[vCP1521] (expressed HIV-1 subtype B Gag and protease) and a boost with a recombinant 
glycoprotein 120 subunit vaccine (AIDSVAX B/E) (Gray et al. 2010). HIV-specific CD4
+
 and 
CD8
+
 T cells resulting from the prime-boost regimen express long term memory markers which 
may be required for participation in further recall responses during HIV infection (Jabbari, Harty 
2006). Data from studies comparing vaccines suitable for use as booster vaccines have indicated 
that recombinant poxviruses vectors are most suitable for development as booster vaccines 
(Hovav et al. 2007, Geiben-Lynn et al. 2008). 
 
Studies evaluating CD8 T cell priming by rBCG indicate excellent memory CD8 T cells are 
generated to the insert. (Russell et al. 2007, van Faassen et al. 2005). These insert-specific cells 
differentiate directly to the central memory phenotype which precludes their detection in an IFN-
γ ELISPOT assay. Such memory cells proliferate in response to a booster vaccine and the 
generated effector cells can then be detected in the IFN-γ ELISPOT assay.  
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3.5.3 Immunogenicity study objectives  
In this study, the vaccination strategy employed a prime with the rBCG vaccines expressing Gag 
and the V3CTL tag followed by a boost with SAAVI MVA-C to determine cellular immune 
responses induced by the rBCG. Effector cells generated by the regimen were detected in an 
IFN-γ ELISPOT assay that used isolated BALB/c mouse splenocytes and Class I and Class II 
specific peptides as specific stimuli. The BCG vector used is a panCD auxotroph engineered to 
express HIV-1 Gag fused to either the α-antigen or the 19kDa signal sequences under the mtrA 
promoter (described in Section 2.10). SAAVI MVA-C is a multi-gene HIV-1 subtype C 
recombinant MVA vaccine that was developed by UCT and SAAVI then manufactured by 
Therion and is now in Phase I Clinical Trials. This vaccine was made available for this study for 
use as a booster vaccine. SAAVI MVA-C expresses HIV subtype C polyprotein Gag-RT-Tat-
Nef (Grttn) and truncated Env (gp150CT) proteins (Burgers et al. 2008). The grttnC gene has 
been inserted into one insertion site in MVA and the gp150CT gene into a second insertion site 
in the same MVA.  The gp150CT is a truncated Env protein with a V3CTL tag (T) for detection 
of immune responses to Env in BALB/c mice and was thus considered to be a suitable vaccine to 
boost the primary immune response induced by the rBCG vaccines. The rBCG prime-SAAVI 
MVA-C boost vaccine regimens were performed as detailed in Table 3.13. A total of 3 
experiments were performed. 
Table 3.13: The vaccination schedule 
Mouse 
group 
(# mice  
per group) 
Day 0 
Prime rBCG 10
7 cfu/200μl (i.p.) 
Day 28Boost  SAAVI 
MVA-C10
4
 pfu/100μl 
(i.m. 50μl each 
tibialis muscle) 
Day 40 
End of experiment 
1 (5) BCG Pasteur ∆panCD  [pEMαGag2V3SV5] MVA Kill, remove spleens 
2 (5) BCG Pasteur ∆panCD  [pEM19Gag2V3SV5] MVA Kill, remove spleens 
3 (5) BCG Pasteur ∆panCD  [pEMGag2V3SV5] MVA Kill, remove spleens 
4 (5) BCG Pasteur ∆panCD  [pEM19Gag2V3SV5] HS MVA Kill, remove spleens 
5 (3) BCG Pasteur ∆panCD  [pCONEPI] MVA Kill, remove spleens 
6 (5) - MVA Kill, remove spleens 
i.p: interperitoneal vaccination. i.m: intramascular vaccination.  
 
3.5.4 Splenocyte numbers and lymphocyte phenotype after vaccination 
Following isolation of mouse splenocytes, FACS was done using antibodies to cell surface 
markers for identifying the phenotype of the lymphocytes in the spleen (see Section 2.10.2). 
Table 3.14 shows the splenocyte numbers and lymphocyte phenotype for the spleens harvested 
for Experiment 3. 
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Table 3.14: The proportion (as % of events in the lymphocyte gate) of B and T cells in the spleens of the mice 
groups vaccinated with the respective rBCG vaccines (experiment 3) 
Mouse 
group   
Neg CD3 CD3/CD4 CD3/CD8 CD4/CD8 
ratio 
CD19 cells/spleen 
(x10
6
) 
Group 1 13.1 39.2 27.9 10.6 2.6 47.7 62 
Group 2 13.0 41.9 30.9 10.5 2.9 45.1 83 
Group 3 13.9 40.8 29.6 10.4 2.8 45.3 75 
Group 4 12.9 45.6 32.3 12.1 2.7 41.5 91 
Group 5 25.8 44.0 30.2 12.9 2.3 30.2 84 
Group 6 17.8 49.3 33.5 14.9 2.2 32.9 49 
Naïve mice 15.9 41.4 28.3 12.3 2.3 42.7 45 
Data on the Naïve mice was obtained from the Vaccine Immunology Laboratory, University of Cape Town.  
 
From these data, comparing the cell populations of the vaccinated animals and the naïve mice, it 
can be concluded that BCG vaccination does not change the composition of the lymphocyte 
population but does increase total cell numbers in the spleen, whereas SAAVI MVA-C does not 
alter spleen numbers. 
3.5.5 Magnitude of V3 CTL-specific and Gag-specific IFN-γ producing CD8 and 
CD4 T cells induced by the prime-boost vaccination regimen  
In order to assess the immune responses elicited by our vaccines, three experiments were 
performed. Mice were primed with the rBCG vaccines. Control vaccine BCG Pasteur ∆panCD 
[pCONEPI] (empty vector) was included. The prime was followed 28 days later with a boost 
with SAAVI MVA-C as indicated in Table 3.14. For all the prime-boost experiments, spleens 
were harvested on day 40. A single cell suspension of splenocytes was then used in an IFN-γ 
ELISPOT assay with BALB/c mouse restricted Gag CD4 and CD8 peptides and the V3CTL 
peptide. Responses to BCG were also determined using a lysate of BCG as the stimulant. The 
assay included responses in the absence of peptide (medium control) and an irrelevant peptide so 
that background responses for the IFN-γ ELISPOT assay could be determined (Section 2.10.4). 
Data from these background responses were used to determine whether responses to a specific 
peptide were or were not positive. For all three experiments the mean background responses 
were 10 ± 5 sfu/10
6
 splenocytes.  Therefore a response of ≥ to this mean background response ± 
1 standard deviation (SD) of this response (i.e. 15 sfu/10
6
 splenocytes) was considered to be a 
positive response. A mean response to the Gag or V3CTL peptides in the IFN-γ ELISPOT assay 
≥ 1.5 fold above that of a control BCG prime and SAAVI MVA-C boost  was considered a 
boosted response.  
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In this study three experiments were done. In the first experiment, the immune responses were 
assessed only 7 days following vaccination of mice with rBCG vaccines. In the second and third 
experiments, the prime-boost strategy listed above was followed. 
 
Experiment 1: 
For this experiment no positive responses to any peptide above the background of 15 sfu/10
6
 
splenocytes were detected (data not shown). However there was a response to the BCG lysate 
(Figure 3.22).  
 
Experiment 2: 
This experiment was a repeat of the first experiment but included an additional positive control 
rBCG vaccine, BCG Pasteur ∆panCD [pEM19Gag2(V3SV5)], provided by the Vaccine 
Development Laboratory. The responses to the HIV peptides in the IFN-γ ELISPOT assay are 
shown in Figure 3.20. Priming with the positive control rBCG vaccine and SAAVI MVA-C 
boost resulted in an excellent response to the V3CTL peptide as well as the GagCD8 peptide of 
7.3-fold and 3-fold respectively above that with a prime with the rBCG control (empty vector) 
and SAAVI MVA-C boost. For the rBCG vaccines prepared for this project the positive V3CTL 
peptide boost responses were only 2-3 fold above that with a prime with the rBCG control 
(empty vector) and SAAVI MVA-C boost. A positive GagCD8 and CD4 peptide boost response 
of 1.6 fold above that with a prime with the rBCG control (empty vector) and SAAVI MVA-C 
boost was only achieved with a prime with the BCG Pasteur ∆panCD  [pEM19Gag2V3SV5] 
vaccine. Despite these positive responses, of concern were the low frequencies of responding 
cells in the IFN-γ ELISPOT assay achieved for the positive control rBCG vaccine. Of which, the 
responses were approximately 40% lower than that expected by the Vaccine Immunology 
Laboratory for this vaccine when used in combination with SAAVI MVA-C. This may have 
been the result of unexplained mouse health problems. 
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Experiment 2: rBCG vaccine prime/SAAVI MVA-C boost. Response to HIV peptides
panBCG[pEMαGag2V3SV5] panBCG[pEM19Gag2V3SV5]
panBCG[pEMGag2V3SV5] panBCG[pCONEPI] (empty vector control)
panBCG[pEM19Gag2V3SV5] HS (Pos control)
 
Figure 3.20: Experiment 2. The V3 CTL-specific and Gag-specific IFN- γ ELISPOT responses on day 40 to a prime 
with the indicated  rBCG vaccines (10
7
 cfu, i.p.) on day 0 and boost with SAAVI-MVA C (10
4
 pfu; i.p.) on day 28. 
Each bar on the graph represents the average SFU/10
6
 splenocytes ± SD (n=3 reactions in the ELISPOT assay) and 
are positive responses ≥ the background responses of 15 sfu/106 splenocytes. pEM19Gag2V3SV5 HS (pos control ) 
depicts the positive control.  
 
Experiment 3: 
A third experiment was performed approximately 9 months after the second experiment. 
Attention was paid to mouse stock and quality of mouse food and bedding for this experiment. 
The responses to the HIV peptides in the IFN-γ ELISPOT assay are shown in Figure 3.21. 
Priming with the positive control rBCG vaccine and a SAAVI MVA-C boost, resulted in the 
response to the V3CTL peptide being 2.6-fold above that with a prime with the rBCG control 
(empty vector) and SAAVI MVA-C boost. No boost response to the Gag CD8 and CD4 peptides 
was observed. A boost of the response to the V3CTL peptide (1.8 fold above the control) was 
achieved with a BCG Pasteur ∆panCD [pEMαGag2V3SV5] prime and SAAVI MVA-C boost 
but no boost of the response of the Gag peptides was observed. For a prime with the BCG 
Pasteur ∆panCD [pEM19Gag2V3SV5] vaccine, a boost of the response to the Gag CD8 peptide 
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was observed (5 fold above the control). No boost response was detected when BCG Pasteur 
∆panCD [pEMGag2V3SV5] was used as the priming vaccine.  
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Experiment 3: rBCG prime/SAAVI MVA-C boost. Responses to HIV peptides
panBCG[pEMαGag2V3SV5] panBCG[pEM19Gag2V3SV5]
panBCG[pEMGag2V3SV5] panBCG[pCONEPI] (empty vector control)
panBCG[pEM19Gag2V3SV5] HS (Pos control)
 
Figure 3.21: Experiment 3. The V3CTL-specific and Gag-specific IFN- γ ELISPOT responses on day 40 after a 
prime with the indicated  rBCG vaccines (10
7
 cfu, i.p.) on day 0 and boost with SAAVI-MVA C (10
4
 pfu; i.p.) on 
day 28. Each bar on the graph represents the average SFU/10
6
 splenocytes ± SD (n=3 reactions in the ELISPOT 
assay) and are positive responses ≥ the background responses of 15 sfu/106 splenocytes. pEM19Gag2V3SV5 HS 
(pos control ) depicts the positive control. 
 
3.5.6 Responses to BCG  
BCG vector responses were also evaluated in the IFN-γ ELISPOT assay using a lysate of BCG 
as the stimulant. All the BCG vaccines used to prime the immune system induced BCG 
responses (Figure 3.22). The second experiment resulted in higher BCG responses as compared 
to the other experiments, with the third experiment eliciting the least responses.  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
80 
 
0
200
400
600
800
1000
1200
Exp 1 Exp 2 Exp 3
panBCG[pEMαGag2V3SV5] panBCG[pEM19Gag2V3SV5] 
panBCG[pEMGag2V3SV5] panBCG[pEM19Gag2V3SV5] HS 
panBCG[pCONEPI] 
rBCG vaccine prime /SAAVI MVA-C boost. BCG responses 
S
F
U
/1
0
6
sp
le
n
o
cy
te
s
 
Figure 3.22: Responses to BCG lysate in the IFN- γ ELISPOT assay on day 40 after a prime with the indicated  
rBCG vaccines (10
7
 cfu, i.p.) on day 0 and boost with SAAVI-MVA C (10
4
 pfu; i.p.) on day 28. Each bar on the 
graph represents the average SFU/10
6
 splenocytes ± SD (n=3 reactions in the ELISPOT assay) and are positive 
responses ≥ the background responses of 15 sfu/106 splenocytes. pEM19Gag2V3SV5 HS depicts the positive 
control. 
 
3.5.7 Responses to SAAVI MVA-C only 
In both experiment 2 and 3 a group of mice vaccinated with SAAVI MVA-C only was included. 
This allowed the effect of a BCG control vaccine prime on responses to SAAVI MVA-C to be 
evaluated.  IFN-γ ELISPOT responses on day 40 to the HIV peptides after a SAAVI MVA-C 
vaccination on day 28 are shown in Figure 3.23. Data from Experiment 2 and 3 as well as data 
from the Vaccine Immunology Laboratory files is compared. The response to the V3CTL 
peptide for the data from Experiment 3 compares favorably with the data from the Vaccine 
Immunology Laboratory. For the experiments in this study responses to RT were not evaluated 
but the Vaccine Immunology Laboratory shows the SAAVI MVA-C vaccine induced a 
predominantly  V3 CTL-specific and RT-specific immune responses with very low responses to 
the Gag peptides.  The data from Experiment 2 is low and may be due to the mice used in the 
experiment. When the responses to HIV peptides after SAAVI MVA-C only vaccination (Figure 
3.23) are compared to that with a BCG control vaccine prime and SAAVI MVA-C boost (see 
Fig. 3.21 & 3.22) it is clear that the immune response to BCG suppresses the response to SAAVI 
MVA-C. 
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Figure 3.23: Responses to HIV peptides in the IFN- γ ELISPOT assay on day 40 after vaccination on day 28 with 
SAAVI MVA-C. The data from the Vaccine Immunology Laboratory are the mean ± SD of 3 replicate experiments. 
The data from Experiment 2 and Experiment 3 are mean values of triplicate responses in the ELISPOT assay.  
 
3.6 Validation of vaccination dose by plating of rBCG vaccine stocks 
Following vaccination of mice, the absorbance readings of the rBCG vaccine stocks were taken 
in order to validate vaccine dose. These vaccine stocks were also serially diluted and plated as 
described in Section 2.10.5.  Both experiments 1 and 2 indicated inconclusive results as the 
colony counts did not follow any trend within each vaccination group. However, in experiment 3 
the actual readings and rBCG colony counts were lower than expected as shown in Tables 3.15 
and 3.16 respectively, whereby the latter table shows that the rBCG numbers of colonies were 
approximately 50% lower than the expected numbers (only at high colony numbers). Both the 
absorbance readings and the number of colonies from plates may possibly indicate that the 
vaccination dose may be lower than expected, though this may be questionable as the lower 
dilutions yielded similar or slightly higher colony counts than expected. 
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Table 3.15: The actual and expected OD600nm readings of prepared vaccine stocks 
rBCG vaccine colony harboring Expected OD600nm Actual OD600nm 
 BCG Pasteur ∆panCD  [pEMαGag2V3SV5] 10.00 6.44 
 BCG Pasteur ∆panCD  [pEM19Gag2V3SV5] 10.05 6.72 
 BCG Pasteur ∆panCD  [pEMGag2V3SV5] 10.60 8.20 
 BCG Pasteur ∆panCD  [pCONEPI] 9.15 7.12 
 
Table 3.16: The rBCG colonies of the vaccine stocks 
rBCG vaccine colony 
harboring 
Expected number of 
colonies 
Actual number of colonies 
Experiment 1 Experiment 2 Experiment 3 
pEMαGag2V3SV5 500 TNTC 9 158 
 50 23 6 30 
 5 4 2 5 
pEM19Gag2V3SV5 500 TNTC 74 203 
 50 17 21 105 
 5 18 11 8 
pEMGag2V3SV5 500 TNTC 40 220 
 50 TNTC 24 76 
 5 27 23 11 
pEM19Gag2V3SV5 * 500 - 44 192 
 50 - 40 57 
 5 - 24 6 
pCONEPI 500 TNTC 75 190 
 50 TNTC 24 72 
 5 28 10 30 
 TNTC: depicts that the colonies were too numerous to count. * indicates positive control 
 
3.7. Evaluation of plasmid stability in vivo  
The splenocytes remaining after the set up of the IFN-γ ELISPOT assay were plated onto 
selective MB7H10 agar plates to culture recovered rBCG. This was done to determine the 
plasmid stability in vivo by restriction enzyme mapping and evaluation of plasmid loss. Small 
scale plasmid isolations were done on the recovered rBCG colonies (20 colonies from each 
vaccine) from mouse splenocytes. The resultant plasmids were mapped using restriction 
endonuclease digestion. On occasions, large scale plasmid isolation was performed on the same 
plasmids and two of these were sequenced as described before.  
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Table 3.17: Evaluation of percentage plasmid loss following culturing of rBCG isolated from mouse splenocytes 
Plasmid  With kanamycin Without kanamycin   % plasmid loss 
Average number of 
colonies 
SD Average number of 
colonies 
SD  
pEMαGag2(V3SV5) 14 0.71  15 0 6.7 
pEM19Gag2(V3SV5) 49 1.41  47.5 0.35 0 
pEMGag2(V3SV5) 46 0.71  37 1.41 0 
pCONEPI 41 0.71  39 0.71 0 
SD: standard deviation 
 
All the rBCG colonies recovered from mouse splenocytes carried stable plasmids as shown in 
Table 3.17, where the rBCG cultures with pEM19Gag2V3SV5 and pEMGag2V3SV5 showed 0% 
plasmid loss. The rBCG colonies harbouring pEMαGag2V3SV5 showed a plasmid loss of 6.7%, 
which may be due to the low colony numbers. Therefore, the small difference in the numbers 
between rBCG cultures plated with or without kanamycin may make a huge difference in the 
percentage plasmid loss. Furthermore, the plasmids isolated from the rBCG within splenocytes 
from all groups of mice vaccinated with  BCG Pasteur ∆panCD  [pEMαGag2V3SV5],  BCG 
Pasteur ∆panCD  [pEM19Gag2V3SV5] and  BCG Pasteur ∆panCD  [pEMGag2V3SV5]  were 
100% stable (see Figure 3.24 to 3.26 and Table 3.18). Some of the plasmids isolated from the 
splenocytes of mice vaccinated with BCG Pasteur ∆panCD [pEM19Gag2V3SV5] (group 2) were 
incompletely digested by NcoI. This is shown by the banding pattern exhibited by a mixture of 
digested and uncut plasmids in lanes 8, 9 and 12 of Figure 3.25A. 
 
Table 3.18: The expected number of fragments and band sizes of mini and maxi preps of plasmids following 
digestion with NcoI 
Plasmid  Restriction enzymes  Expected no. of bands Expected band sizes in bp 
pEMGag2(V3SV5) NcoI 2 1398, 596 
pEM19Gag2(V3SV5) NcoI 2 1398, 5105 
pEM Gag2(V3SV5) NcoI 2 1398, 4970 
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Figure 3.24: Restriction enzyme mapping of pEMαGag2(V3SV5) plasmid DNA extracted from rBCG isolated from 
mouse splenocytes. Plasmid DNA was digested with restriction enzym  NcoI. A & B: Lanes 1 and 14: 1kb DNA 
molecular weight marker; Lanes 2 and 13: positive control, original, untransformed DNA; Lanes 3-12: plasmid 
DNA extracted from rBCG isolated from mouse splenocytes.  
 
1        2          3          4          5        6         7         8         9        10        11        12       13    14 
1        2          3          4          5        6         7         8         9        10        11        12       13    14
5105 bp
1398 bp
5106 bp
1398 bp
A
B
 
Figure 3.25: Restriction enzyme mapping of pEM19Gag2(V3SV5) plasmid DNA extracted from rBCG isolated from 
mouse splenocytes. Plasmid DNA was digested with restriction enzyme NcoI. A & B: Lanes 1 and 14: 1kb DNA 
molecular weight marker; Lanes 2 and 13: positive control, original, untransformed DNA; Lanes 3-12: plasmid 
DNA extracted from rBCG isolated from mouse splenocytes.  
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Figure 3.26: Restriction enzyme mapping of pEMGag2(V3SV5) plasmid extracted from rBCG isolated from mouse 
splenocytes. Plasmid DNA was digested with restriction enzyme NcoI. A & B: Lanes 1 and 14: 1kb DNA molecular 
weight marker; Lanes 2 and 13: positive control, original, untransformed DNA; Lanes 3-12: plasmid DNA extracted 
from rBCG isolated from mouse splenocytes.   
 The V3 CTL boost responses were lower than expected and the Gag CD8 responses were higher 
following priming with  BCG Pasteur ∆panCD   [pEM19Gag2V3SV5]. We therefore sought to 
address this by further restriction enzyme mapping of pEM19Gag2V3SV5 extracted from rBCG 
recovered from mouse splenocytes as well as sequencing this entire insert; mtrA-19kDa signal 
sequence-HIV-1 gag-V3 CTL epitope-SV5 monoclonal antibody tag with the primers shown in 
Table 3.19. This was done in order to determine whether a deletion, insertion of gene 
rearrangement might have occurred between the Gag CD8 and the V3 CTL epitopes. The 
restriction enzyme mapping in Figure 3.27 shows that the recovered plasmids were 100% stable 
and there were no mutations in the sequenced insert (data not shown). 
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Table 3.19: Primers, their sequences and the sides of binding on the constructed plasmids 
Primer series  Primer sequences  Binding sites on plasmids  
pCONEPI-F TGGCGAACTCCGTTGTAGTG 60bp upstream of the XbaI site in the vector backbone 
 
pCB119-F CCATATGAAGCGTGGACTGAC About 160bp downstream of ATG of pEM19 vectors (for 
only pEM vector backbones) 
pFRF 4 ACACCAAGGAGGCCCTGG About 5097bp on pEM19Gag2V3SV5 (suitable for Gag1 or 
Gag2 plasmids) 
pFRF 6  TCCGCGACTACGTGGACC About 5684bp on pEM19Gag2V3SV5 (suitable for Gag1 or 
Gag2 plasmids) 
pFRF 7 CGCAAGAAGGGCTGCTGG About 6034bp on pEM19Gag2V3SV5 (suitable for Gag1 or 
Gag2 plasmids) 
14 
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Figure 3.27: Restriction enzyme mapping of pEM19Gag2(V3SV5) plasmid DNA. Lanes 1 and 14: 1kb DNA 
molecular weight marker; Lanes 2, 5, 8 and 11: positive control, original, untransformed DNA; Lanes 3, 6, 9 and 12: 
plasmid DNA extracted from rBCG isolated from mouse splenocytes (clone 8); Lanes 3, 6, 9 and 12: plasmid DNA 
extracted from rBCG isolated from mouse splenocytes (clone 16). 
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Table 3.20: The expected number of fragments and band sizes of pEM19Gag2(V3SV5) plasmid following double 
digestion with various enzymes 
Plasmid  Restriction enzymes  Expected no. of bands Expected band sizes in bp 
pEM19Gag2(V3SV5) XbaI/HpaI 2 2457, 4046 
SnaBI/EcoRV 2 1500, 5003 
BamHI/XbaI 2 1263, 5242 
XbaI/ApaI 2 862, 5641 
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CHAPTER 4: DISCUSSION 
The aim of the study was to select a stable plasmid backbone for the construction of rBCG 
expressing HIV-1 Gag under the control of different promoters and with different leader 
sequences. These shuttle vectors stability and immunogenicity was then compared.    
4.1 Construction of stable vaccine shuttle vectors 
E. coli-mycobacterium shuttle vectors have been widely used for the delivery of foreign genes 
into BCG (Chege et al. 2009, Ami et al. 2005, Cayabyab et al. 2009). In developing such vectors: 
the choice of promoter, such as mtrA or hsp60 (Zahrt, Deretic 2000); codon optimization of the 
foreign gene for expression in mycobacteria (Kanekiyo et al. 2005); the use of leader sequences 
(19kDa or α) to facilitate secretion of the foreign antigen (Al-Zarouni, Dale 2002, Himmelrich et 
al. 2000) and the use of episomal or integrative vectors are amongst the plasmid vector features 
that may affect vector stability.  
 
In our laboratory, it was shown that from the same pCB119 vector backbone, there was an 
increased expression of Gag driven by the mtrA promoter as compared to the M. tuberculosis 
katG promoter (Thomas 2005). It was also demonstrated that vaccination with rBCG harboring 
plasmid pRT106 (pCB119 backbone, 19kDa signal peptide, mtrA promoter and gag) elicited 
better cellular and humoral immune responses as compared to pRT108 (same vector, but with 
katG promoter) in mice. Such responses were attributed to increased gag expression from a 
relatively stable rBCG vaccine (Thomas 2005). Another study conducted in our lab in non-
human primates by Chege et al. (2009) gave similar results, where immune responses following 
priming with the same rBCG and boosting with Gag VLPs were evaluated. The IFN-γ response 
to Gag peaked 2 weeks after the boost to a mean of 677 and 274 SFU/10
6
 PBMC for BCG 
[pRT106] and BCG [pRT108] primed baboons respectively. Lower responses in the IFN-γ 
ELISPOT assay after the prime with RT108 and boost with Gag VLPs suggests levels of Gag 
expression determine the success of priming the immune system. It has therefore been speculated 
that the stability and increased expression levels of Gag may also be enhanced by cloning it into 
a more stable vector backbone.  
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4.2 Selection of an optimal episomal vector  
High expression levels of heterologous antigens can lead to a toxic and/or a metabolic burden on 
bacterial cells (Joseph et al. 2010, Al-Zarouni, Dale 2002). This leads to slower growth rates and 
can result in genetic instability of the gene being expressed, since as soon as a mutant that does 
not express the heterologous antigen arises, it will have a growth rate advantage and will 
therefore out-compete the rest of the colony or culture. On solid media, slow growth rates are 
normally indicated by small colony size. This is reflected in relative colony sizes wherein; the 
larger the colonies, the more „healthy‟ the recombinants and the smaller the colonies, the more 
stressed or „unhealthy‟ the recombinants are. Such a phenomenon was exploited in this study 
whereby fitness of the shuttle vectors with different vector backbones was evaluated by growth 
of recombinant M. smegmatis on solid media.  
 
In the current study, the colony sizes were rated relative to the positive control with the 
pCONEPI plasmid, as it is an empty vector only expressing the kanamycin resistance gene. The 
reason being this vector would experience no metabolic burden as it does not express any foreign 
genes such as gag. In this study, it was evident that M. smegmatis [pCB119Gag] colonies grew at 
a slower rate than M. smegmatis [pEM19Gag] colonies, resulting in slightly smaller colonies on 
the transformation plates. This was also observed in liquid medium and may be attributed to the 
metabolic burden placed on the cell by the lysA gene expression, thus resulting in retarded 
growth rate. An interesting observation from this study is that, even when the codon optimised 
gag was inserted into both vectors (pCB119 or pEM19), in liquid media M. smegmatis 
[pCB119Gag] cultures still grew at a slower rate than M. smegmatis [pEM19Gag], thus 
indicating vector fitness was enhancement once the lys A gene was removed from the backbone. 
 
An accurate measurement of plasmid stability is hard to achieve because of the well-known fact 
that mycobacteria exist as clumps that are very difficult to disperse (Parish, Stoker 1998). This 
then makes it difficult to measure growth rates in liquid culture by means of absorbance 
readings. Therefore, growth rates cannot be solely used to evaluate stability, but can infer vector 
fitness. For this reason, it has been documented that to determine plasmid stability in 
mycobacteria; cultures are serially passaged by re-inoculating into fresh media in the absence of 
antibiotic until the bacterial cells have passed through a number of generations and then these are 
plated on both selective and non-selective solid media (Bourn et al. 2007, Griffin et al. 2009). 
This will reflect on the plasmid retention, which indicates plasmid stability. In this, study the 
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recombinant M. smegmatis (after 10 generations) cultures were serially plated onto both selective 
and non-selective solid media (agar plates) and colonies were counted to evaluate percentage 
plasmid loss as an indicator of stability after a number of generations, as well as to infer possible 
rearrangements.  
 
What was striking was that the cultures harbouring the pCB119Gag vector showed a great deal 
of plasmid loss (54%) as compared to those with pEM19Gag. This indeed revealed the 
detrimental effects of the presence of hsp60-lysA on vector fitness and stability. For these 
reasons, it was speculated that pCB119 vector backbone was not very stable and we therefore 
based our vectors on the pEM backbone.  
 
4.3. Construction of rBCG shuttle vectors  
In order to assess the effect of addition of signal peptides , inducible promoters as well as codon 
optimised Gag on vector fitness in vitro and also to determine their stability and immunogenicity 
in M. smegmatis and BCG respectively six vectors with differing features were successfully 
designed and constructed. The first three shuttle vectors derived from the following parental 
plasmids; pEMGag2(V3SV5)gp33-41, pEM19Gag2(V3SV5)gp33-41 and 
pEMGag2(V3SV5)gp33-41 were successfully constructed. The other three shuttle vectors 
pEM(V3SV5), pEM19(V3SV5) and pEM(V3SV5) were designed such that they lacked the 
HIV-1 gag gene and were constructed from the first three vectors. These constructs were used as 
controls, most especially during the evaluation of Gag expression by HIV-1 p24 assays. Three of 
these vectors were selected in order to determine the influence of the signal peptides on the 
immunogenicity of HIV-1 Gag antigen following vaccination of BALB/c mice with such rBCG 
vaccines. In essence the vectors were constructed such that they contained unique features that 
will allow for induced expression of codon optimized gag, which may be directed to the cell 
membrane, secreted or remain in the cytoplasm. The addition of these features on vector fitness 
and in vitro stability was evaluated before vaccination of mice.  
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4.4 Determination of vector fitness by growth rates and evaluation of plasmid 
stability 
In this study, we evaluated the effect of addition various shuttle vector features on vector fitness. 
Promoter elements such as inducible mtrA as well as constitutive hsp60 and pscmyc promoters, 
have received particular attention, as these regulate the level of expression of a foreign gene as a 
function of promoter strength and the timing of expression according to promoter activity. Other 
vector features that also influence expression levels include leader sequences (19kDa or α) used 
to target the protein within the BCG cell (Zahrt, Deretic 2000, Via et al. 1996) and inserted 
foreign DNA sequences (Dennehy et al. 2007). It has been shown that stability of recombinant 
BCG antigen delivery systems is influenced by these shuttle vector features (Joseph et al. 2010). 
 
Use of episomal vectors in rBCG has been shown at times to result in high levels of stability in 
vitro. For example, Horwich et al. (1985) showed that plasmids responsible for expressing M. 
tuberculosis α-antigen in BCG were stable over six consecutive 4-week cultures without 
antibiotic selection and changes in the level of expression. In addition, Kawahara et al. (2002) 
were able to show that rBCG could express the antigen containing the 19 amino acid V3 peptide 
even after at least 450 passages. However, some studies have emphasized the deleterious effect 
of hsp60 promoter on the expression of some foreign genes in mycobacteria (Joseph et al. 2010, 
Dennehy et al. 2007), which may pose a disadvantage relative to the inducible mtrA promoter 
that has lower activity during in vitro growth, but is induced on infection of macrophages (Al-
Zarouni, Dale 2002, Zahrt, Deretic 2000) thus driving the expression of a foreign antigen at a 
time when the antigen could be exposed to the immune system. 
 
Carroll et al. (2010) showed that fluorescence from the high copy number plasmids expressing 
Coral Discosoma striata red (DsRed) reporter genes under the hsp60 promoter was not higher 
than for the low copy number plasmid in M. smegmatis. Plasmids recovered from non-
fluorescent colonies had deletions in the promoter-fluorescent protein region, whereas plasmids 
recovered from the coloured colonies appeared intact, confirming that loss of expression was due 
to the acquisition of deletions in the plasmids. The group also indicated that using psmyc promoter 
resulted in 100% of all transformants fluorescing when low copy number plasmids were 
transformed into M. tuberculosis. On the contrary, hsp60 driven expression of the reporter gene 
resulted in fluorescence of only 5% of the transformants. After three passages of recombinant M. 
tuberculosis, there was no decrease in the fluorescence intensity of the Psmyc-reporter plasmids. 
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However, hsp60 promoter-driven expression decreased over time, suggesting accumulation of 
deletions or mutations in the plasmid (Carroll et al. 2010) thus indicating lack of vector fitness. 
Gall, Barker (2006) also showed that foreign antigen expression under the control of another 
strong mycobacterial promoter such as G13 caused deletions of upstream promoter regions, thus 
resulting in 20-40 fold reduction of GFP expression over all growth phases.   
 
Similarly, in our study high levels of constitutive expression of Gag driven by either the hsp60 or 
psmyc promoter contributed to reduced vector fitness, thus resulting in small or no colonies. This 
is in contrast with the inducible expression of mtrA promoter that resulted in large, healthy 
looking colonies. This could be attributed to reduced HIV-1 Gag expression in vitro, which in 
turn leads to a lower metabolic burden on the recombinant mycobacteria. We also evaluated the 
mtrA promoter driven expression of HIV-1 Gag by culturing rM. smegmatis cells and then 
isolating the cell free extract to evaluate the Gag p24 levels. The three recombinants expressing 
Gag from this inducible promoter expressed far lower levels of p24 in vitro as compared to the 
recombinant mycobacteria expressing Gag from the constitutive hsp60 promoter, thus 
emphasising that use of mtrA may result in low level in vitro expression of foreign antigens. In 
another study by Zahrt, Deretic (2000), S1 nuclease protection of total cellular RNA-ssDNA 
probe hybridisation products and primer extension analysis reflected that mtrA was expressed at 
low levels during in vitro growth.   
 
Extracellular foreign antigen expression by signal peptides may result in higher expression levels 
than intracellular expression of the same antigen (Al-Zarouni, Dale 2002). This is because 
expressed foreign antigens, which remain within the cell, can lead to increased metabolic burden 
or protein toxicity, whereas extracellular secretion or lodging of these antigens by signal peptides 
into the membrane may result in reduced protein toxicity, thereby increasing vector fitness.  
 
On the contrary, in this study, it was shown that the recombinant M. smegmatis 
[pEMGag2V3SV5] colonies (with no signal peptide) had similar colony size as tranformants 
harbouring vectors with either 19kDa or α-antigen signal peptides. This was not expected and 
may have been because the plasmid had deletions that gave such mutants a growth advantage 
over the others. There was no indication of this in our vaccine stocks; however, after 10 
generations in liquid of culture M. smegmatis [pEMGag2V3SV5] showed 11% plasmid loss as 
compared to 0% of pEMGag2V3SV5 plasmid, which was not a great loss. Increased expression 
of HIV-1 p24 Gag from M. smegmatis [pEMGag2V3SV5] cell free extracts indicated that 
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secretion of foreign antigen may result in higher expression levels. Similarly, Al-Zarouni, Dale 
(2002), provided evidence that the 85A (α-antigen) secretion signal peptide markedly enhanced 
the levels of cell-associated product, while the 19-kDa signal sequence had little effect on gene 
expression. 
 
One strange observation was that M. smegmatis [pEM19Gag2V3SV5] cultures grown with 
selection in liquid medium exhibited a slightly slower growth, which was in contrast with the 
relative „health‟ seen when the same culture was grown on solid medium. One possible reason, 
which could not be explained, would be that the cultures harbouring such a vector (with the 
19kDa signal peptide) may show differential growth patterns in either liquid or in solid media. 
One important factor to note is that, since the α-antigen and 19kDa direct the expression of 
antigens to the extracellular matrix and membrane respectively, the accurate determination of 
Gag expression levels may be limited to that only intracellular HIV-1 Gag p24 levels were 
measured.  
 
Another possibility of different expression levels from the cultures harbouring plasmids with 
different signal sequences may be due to the presence or absence of „downstream boxes‟ (DB). 
These are 12-15 base long sequences downstream of the mRNA initiation codon. This box is 
complementary to the 16s RNA thus enhancing the binding of the ribosome to the RNA and 
translation initiation. Rush, Steyn 2005 used codon optimised DB and a strong katG promoter 
driving luciferase expression to evaluate their effect on translation. This group showed increased 
expression of luciferase from plasmids without Shine Dalgarno (SD), but with DB in both E. coli 
and M. smegmatis. DB-specific effect of translation was also seen as plasmids with E. coli 
optimised DB showed increased expression in E. coli than in M. smegmatis and the reverse effect 
was seen as when M. smegmatis DB optimised plasmids were transformed into both M. 
smegmatis and E. coli (Rush, Steyn 2005). The specificity and efficiency of DB has previously 
been shown in E. coli (Sprengart et al. 1996). Since the constructs used in this study did not have 
any obvious ribosome binding sites, it was found out that only pEM19Gag2V3SV5 plasmid 
contained a potential DB (though it was only about 60% identical to other mycobacterial down 
stream boxes), which did not enhance Gag expression.  
 
We showed that the addition of HIV-1 gag did not have any effect on vector fitness, but its 
codon optimisation did enhance vector fitness as seen by larger colonies. The increase in colony 
size may be due to codon optimisation of the gene for expression in mycobacteria. As the mtrA 
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promoter expresses at such a low level in culture, levels of Gag expression were probably very 
low and therefore this could be why little or no difference was seen when gag was included in 
the vector.  
 
Similarly, when grown in non-selective medium (without kanamycin), all the cultures harbouring 
vectors with the codon optimised gag showed the faster exponential growth as compared to non-
codon optimised M. smegmatis [pEM19Gag] cultures, which also only 8%  plasmid loss. From 
these results, we observed that codon optimization of gag resulted in increased vector fitness and 
plasmid stability, which is in agreement with the studies carried out by Kanekiyo et al. (2005), 
whereby the group showed that codon optimization of gag resulted in increased expression 
levels.  
 
4.5. Immunogenicity of rBCG vaccines in mice  
Dennehy et al. 2007 showed the absence of antibodies against rotavirus following vaccination of 
mice with rBCG expressing antigens from episomal vectors with either the M. leprae 18kDa 
promoter and α- antigen signal peptide (pCB112-Edim6) or the mtrA promoter and M. 
tuberculosis 19kDa signal sequence (pCB119-Edim6). The group proposed that the lack of 
antibodies might be attributed to lack of antigen expression, low export of this antigen or 
inability of lodging to the membrane, and its subsequent lack of presentation to B cells. The mice 
were also not protected from challenge virus, which collectively indicated that levels of antigen 
expression might have an effect on the immune responses. 
 
Similar results are obtained in this study whereby in this case, low cell mediated immune 
responses were elicited by rBCG vaccine expressing HIV-1 Gag from episomal vectors with 
either the 19kDa or  α–antigen signal sequences as well as those without any leader peptides. 
This was the case with all the three experiments. In the first experiment, since the mice were not 
boosted with SAAVI MVA-C vaccine, the low immunogenicity of the vaccines may be 
accounted for by lack of or delayed immune activation of the CD8 T-cells. Russell et al. (2007) 
showed that CD8+ T cells that differentiate during infection of mice with BCG undergo limited 
activation during the first 7 days of infection, the response peaks during the third week of 
infection, followed by a protracted and reduced contraction phase. The group proposed that the 
delay in generating a rapid primary CD8+ T cell response against BCG could be due to the 
induction of inappropriate inflammatory signals by BCG, or due to the reduced generation of 
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antigenic load in vivo. However, this may not entirely apply to this study as stimulation of 
splenocytes from vaccinated mice with a BCG lysate did induce BCG-specific responses. In the 
second experiment, since the BCG-specific responses as well as low magnitude Gag-specific 
responses were also induced and also the SAAVI MVA-C boosted the responses, the health of 
the mice may have been an issue that led to reduced immunogenicity of the vaccines.    
 
Comparing our results in experiment 3, vaccination with BCG Pasteur ∆panCD 
[pEMαGag2V3SV5] resulted in the highest (a positive V3 CTL boosted responses), which may 
be due to the secreted nature of Gag. The increased Gag CD8
+ 
T-cell responses elicited by BCG 
Pasteur ∆panCD [pEM19Gag2V3SV5] may have been elevated because of low immune-
dominant V3 CTL immune responses. M. smegmatis [pEM19Gag2V3SV5] cultures grown with 
selection in liquid medium exhibited slow growth which was in contrast with the relative „vector 
fitness‟ (larger colony size) seen when the same culture was grown on solid medium. Therefore, 
since the vaccines were prepared as liquid cultures, the same scenario may have been 
experienced, whereby the rBCG with the same plasmid may have showed slowed growth, with 
low Gag expression that may consequently have a negative effect on immunogenicity. This may 
possibly explain why vaccination with BCG Pasteur ∆panCD [pEM19Gag2V3SV5] elicited low 
immune responses to V3 CTL, however the disparity in the growth patterns of cultures in either 
liquid or solid media could not be explained. 
 
Several other factors may have contributed to the low immunogenicity of these vaccines; firstly, 
vector stability in vivo may have been an issue. However, following isolation of plasmids from 
rBCG recovered from mouse splenocytes, we discovered that all the plasmids were 100% stable, 
thereby ruling out vector stability as a contributing factor. Another factor that may have 
contributed to low immunogenicity of our vaccines may be low vaccination dose. The remainder 
of the vaccines following vaccination showed markedly lower absorbance readings than 
expected and the rBCG colonies plated from the vaccine stocks before vaccination were 
unexpectedly low, only at the higher dilutions. These then reflect that the vaccine dose may have 
been lower than the expected 1 x 10
7
cfu/mouse, thereby leading to reduced immunogenicity 
levels. 
 
Similarly, Lesellier et al. (2006), when evaluating the safety and immunogenicity of BCG 
Danish strain 1331 in European badgers (Meles meles) showed that repeat injection of the lower 
BCG dose induced a response of reduced magnitude and persistence compared with the high 
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dose vaccination, despite prior sensitization to BCG. On the contrary, both Phase I studies of a 
recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and 
Pol from subtype B and multiclade Env,  given alone showed no significant effect of rAd5 
dosage on immunogenicity endpoints (Jaoko et al. 2010, Peiperl et al. 2010). The disparity in 
these results may be argued that the type of vector used may be influential in the magnitude and 
breadth of immune response elicited. For this reason, since we used a bacterial vector, the 
vaccine dose may have played a critical role in the immunogenicity of our vaccines, though the 
statement may not be conclusive. Russell et al. (2007) also suggested that for pathogens that 
display poor in vivo growth (such as BCG), the dose of the pathogen can enormously modulate 
the differentiation of CD8+ T cell response. 
 
4.6 Conclusions and future work  
This study showed that the use of the pEM19 vector backbone as opposed to pCB119 vector 
backbone resulted in increased vector fitness and stability. In addition, the use of signal peptides 
to direct expression foreign antigens to either the extra-cellular matrix or the cell wall may be 
beneficial in enhancing the immune responses elicited by rBCG vaccine harbouring such vectors. 
Therefore, as seen in this study and many others, the choice of vector backbone, the use of 
inducible promoters, antigen secretion to enhance the immunogenicity and to prevent foreign 
proteins from becoming toxic to BCG and codon optimization of the foreign gene to increase 
expression are some of the factors that enhance vector fitness and stability. In the immunology 
experiment 2, a positive GagCD8 and CD4 peptide boost response was only achieved with a 
prime with the BCG Pasteur ∆panCD [pEM19Gag2V3SV5] vaccine. Despite these positive 
responses, of concern were the low frequencies of responding cells in the IFN-γ ELISPOT assay 
achieved for the positive control rBCG vaccine. In experiment 3, a boost of the response to the 
V3CTL peptide was achieved with a BCG Pasteur ∆panCD [pEMαGag2V3SV5] prime and 
SAAVI MVA-C boost but no boost of the response of the Gag peptides was observed. No boost 
response was detected when BCG Pasteur ∆panCD [pEMGag2V3SV5] was used as the priming 
vaccine. Therefore, BCG Pasteur ∆panCD [pEMαGag2V3SV5] maybe a promising vaccine as 
seen by increased immune responses to the V3 CTL epitope as well as by the increased Gag p24 
levels following transformation of M. smegmatis with the same vector.  
 
The use of small foreign DNA sequences (conserved epitopes) instead of the full-length gag may 
be considered in the future to increase epitope coverage in order to increase antigen specific 
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immune responses. Furthermore, the detailed profiling of cell-mediated immune responses 
elicited by these vaccines may be a way forward, not ruling out the validation of vaccine dose 
before vaccination. Most importantly, in this study various signal peptides and the mtrA 
promoter were included in the vectors, therefore future studies could include the comparison of 
Gag expression and localization from these rBCG vaccines using in vitro mouse derived 
macrophage cultures as well as use of fluorescent microscopy in order to better understand the 
relationship between antigen presentation and the nature of the immune response elicited. 
Moreover, transcriptome analysis (mRNA profiling) would also be an informative approach in 
order to evaluate the different messages relayed by such vaccines in mice.   
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